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ABSTRACT
Destabilization of the endothelial monolayer lining blood vessels has profound consequences on 
organismal homeostasis. Vascular instability plays a well-known role in the pathophysiology of diseases 
from sepsis to stroke. A variety of factors are known to influence endothelial function, including the 
extracellular milieu, biomechanical factors, various molecular pathways, as well as genetic elements.
Many factors promoting vascular instability have been described; however, far fewer studies have 
identified factors promoting stability. No overarching theory of vascular stability has yet been proposed 
that takes into account extracellular, biomechanical, molecular, and genetic variables.
In this dissertation, I detail studies of extracellular matrix cues, molecular pathways, and genetic 
factors in an attempt to identify commonalities associated with regulation of vascular stability. I first show 
that the extracellular matrix protein elastin normalizes endothelial cell function. Next, I demonstrate a 
critical role of the small GTPase ARF6 in mediating cytokine-induced endothelial instability. I also 
identify a crucial role of ARF6 in mediating transduction of mechanical signals in the endothelium.
Finally, I describe a central role of various genes associated with a human disease, Cerebral Cavernous 
Malformation (CCM), in endothelial stability.
During the course of these studies, I developed and utilized a variety of tools not often found in 
molecular biology labs. I built new apparatuses and wrote software programs to answer the questions I 
had, rather than relying on what had already been built by others. Perhaps my largest contribution to the Li 
laboratory has been to propagate the use of these new systems to molecular biologists who may have a 
better capability to ask important questions, and who now have the ability to answer their own questions 
more quickly, more efficiently, and without the inherent bias associated with the standard protocols used in 
the majority of molecular biology labs.
Finally, during my last two years in the laboratory, I further refined and integrated the tools I 
developed with new tools available from the Broad Institute to quantitatively evaluate endothelial stability
through measurement of both structural and functional phenotypes. Using quantification of structural and 
functional phenotypes, I identified multiple drugs that ameliorate in vitro CCM models, and found two 
drugs that significantly reduce the formation of lesions in murine models of CCM disease. Further, I found 
that one of these compounds was protective against diverse destabilizing cues in the endothelium. These 
discoveries are important for the study of CCM disease, for patients with CCM disease, and have 
implications for many other diseases in the future.
Overall, my studies resulted in specific new mechanistic insights into a wide-variety of factors that 
promote endothelial stability. More important is the development of a multilayered strategy and platform 
that can be applied to study effects of extracellular, biomechanical, molecular, and genetic cues on the 
endothelium either alone or in any combination. In the immediate future, this platform will serve as a 
vehicle for creating an over-arching model of vascular stability. Beyond this application, this same 
platform can be rapidly scaled to answer broad questions about factors crucial in health and disease across a 
wide variety of other cell and organ types. I intend to use the approach I developed and describe in my 
dissertation to try to untangle how all genes, all proteins, all diseases, and all drugs interact -  a lofty goal to 
be sure.
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INTRODUCTION
The endothelium acts as the gatekeeper between the vascular space and the tissue in each organ of the 
body. Further, the endothelium serves critical roles as both an organ of hemostasis and of immune response. 
Activation of various pathways within the cells of the endothelium can lead to alterations in the transport of 
compounds across the endothelium, provocation or inhibition of hemostasis, or an immune response that is either 
too minimal or so strong that it leads to unnecessary tissue destruction. A wide-variety of cues, both chemical 
and physical, informs the state of the endothelium.
First, the extracellular milieu, especially the components of the extracellular matrix, can have a 
profound role in shaping endothelial function. The various extracellular matrix components are secreted by the 
endothelium and by its neighbors. Extracellular matrix components affect the endothelium through direct 
receptor-mediated action and by modulating the biophysical environment in which the cells reside. In this 
dissertation, I illustrate the roles of one such matrix protein, elastin, in promoting endothelial stability.
A variety of different signaling pathways play a well-describe role in endothelial stability such as 
sphingosine-1P via its canonical receptor or angiopoietin through Tie-2. The endothelial-specific receptor 
ROBO4 has been shown to play a role in modulation of an activated state in the endothelium, ostensibly through 
actions on the small GTPase ARF6. I show in this dissertation that activation of ARF6 tends to move the 
endothelium toward an activated state, while inhibition of ARF6 promotes a less-reactive quiescent state.
Another key mediator of endothelial stability is the biophysical environment which consists of cyclic 
strain on the endothelium, especially in the larger vessels, as well as flow-mediated shear stresses across the 
endothelium of all vessels large and small. Abnormal magnitudes of shear stress, or oscillation of shear stresses, 
can result in activation of a variety of pathways that promote an ‘activated’ endothelial state in which the 
endothelial monolayer becomes leaky to both protein and fluid, in which the endothelium can become pro- 
thrombotic, and in which adhesion and diapedesis of inflammatory cells is increased. I describe in this 
dissertation the role of ARF6 in regulation of the endothelial response to shear stresses.
2Lastly, genetics can play a major role in the predisposition of the endothelium toward a more activated 
or quiescent state. Genetic mutations can play an indirect role, as is the case in familial hypercholesterolemia. 
Mutations in the gene LDLR lead to an increase in lipoproteins in the serum which lead the endothelium down a 
self-promoting inflammatory path. Other genetic mutations associated with human disease can have a direct 
effect on endothelial stability such as the role of ENG or ALK1 in hereditary hemorrhagic telangiectasia (HHT). 
We study loss of function of genes associated with another human disease, cerebral cavernous malformation 
(CCM), as a highly isolatable model of endothelial instability. In this dissertation, I characterize the role of two 
genes associated with CCM disease, CCM2 and CCM3, on vascular stability.
As a bioengineer, my approach to studying myriad different vascular stability cues was different 
from the typical molecular biologist. I developed new assay systems to test the questions at hand. Most 
importantly, as my studies progressed, I moved assays toward an automated higher-throughput approach. 
The motivation for this was to reduce bias inherent in everything humans do, and to enable the laboratory 
to simultaneously ask and answer many more questions. Along with a push toward automation and higher- 
throughput, I worked to help my colleagues develop automated analysis algorithms to answer their own 
research questions. Through this concerted effort, I built a library of high throughput assays and tools that 
have enable the Li Lab and our collaborators to assess many more variables in a rapid and repeatable 
manner. By optimizing these various assays and identifying and acquiring additional analysis tools from 
other laboratories, I have made a lasting contribution to the laboratory. As my final project in the 
laboratory, I amassed and integrated all of these tools to develop a high-throughput platform that enables 
an unbiased, target-independent, non-hypothesis-driven approach to drug discovery. In this dissertation, I 
describe this platform and demonstrate its power by identifying two drugs that subsequently rescue CCM 
disease in mice. Finally, I suggest that this platform has potential for the treatment of diseases on a scale 
that has not previously been accomplished.
As with any scientific endeavor, the data published here are in many cases the result of work by 
multiple people. In Chapter 1, I describe the use of tropoelastin as a novel coating for intravascular 
devices. This paper, of which I am co-first author, was written by me. Additionally, I helped to obtain the 
data in Figure 1.4, and developed a new assay and new software to obtain all the data in Figure 1.5. In 
Chapter 2, in which we describe the role of the small GTPase ARF6 in vascular stability, I wrote this paper,
3and contributed the original data to multiple figures, including Figure 2.1, Figure 2.4, and Supplementary 
Figures 2.2, 2.5, 2.7, 2.8, and 2. 9. In Chapter 3, I describe the role of ARF6 in mechanotransduction. I 
obtained all data shown in this chapter, with the exception of data in Figure 3.3, for which I relied on close 
collaborators who performed some of the final work without me. In Chapter 4, I describe the development 
of a mouse model for CCM disease. I played a major role in writing this paper, and also obtained or helped 
to obtain the original data used in Figures 4.2, 4.3, and 4.7, as well as supplemental Figure 4.9. In Chapter 
5, I describe the identification of novel treatments for CCM disease. I obtained all of the data used in this 
paper, with the exception to any western blots, for which I obtained help from my colleagues in the 
laboratory. This paper has been submitted, but not yet accepted, for publication as of the time of 
submission of this dissertation.
CHAPTER 1
NOVEL APPROACH FOR ENDOTHELIALIZING VASCULAR 
DEVICES: UNDERSTANDING AND EXPLOITING 
ELASTIN-ENDOTHELIAL INTERACTIONS
The following chapter was reprinted with permission from the Annals of Biomedical Engineering. 
I was co-first author of this paper with Brent D. Wilson. In addition, the other authors were Lise K. 
Sorensen, Margaret Y. Guilhermier, Melissa Clinger, Linda L. Kelley, Yan-Ting E. Shiu, and Dean Y. Li. 
This article was originally published in the Annals of Biomedical Engineering, 2011 Jan;39(1):337-346. 
This manuscript details the stabilizing role of elastin, an extracellular matrix component, on the 
endothelium.
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Abstract— Elastin is an essential com ponent o f  arteries which 
provides structural integrity and instructs sm ooth muscle 
cells to  adopt a quiescent state. D espite interaction o f  
endothelial cells w ith elastin in the internal elastic lamina, 
the potential for exploiting this interaction therapeutically 
has not been explored in detail. In this study, we show  that 
tropoelastin  (a precursor o f  elastin) stim ulates endothelial 
cell m igration and adhesion m ore than  sm ooth  m uscle cells. 
The biological activity o f  tropoelastin  on endothelial cells is 
contained in the V G V A PG  dom ain and in the carboxy- 
term inal 17-amino acids. W e show that the effects o f  the 
carboxy-term inal 17 am ino acids, but no t those o f  
V G V A PG , are mediated by intcgrin av^ 3. W e dem onstrate 
that tropoelastin  covalently linked to  stainless steel disks 
prom otes adhesion o f  endothelial p rogenitor cells and 
endothelial cells to  the m etal surfaces. The adherent cells on 
the tropoelastin-coatcd metal surfaces form  m onolayers that 
can w ithstand and respond to  arterial shear stress. Because o f  
the unique effects o f  tropoelastin  on endothelial and  sm ooth 
muscle cells, coating intravascular devices with tropoelastin 
may stim ulate their cndothclialization, inhibit sm ooth  muscle 
hyperplasia, and  im prove device perform ance.
Keywords— Arteries, 
Restcnosis.
E ndothelium , Receptors, Stents,
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INTRODUCTION
Complications of intracoronary stent placement 
include thromboembolic events and neointimal 
hyperplasia due to smooth muscle ccll hypcrprolifcra- 
tion, leading to in-stent restcnosis. The central role of 
the vascular endothelium in preventing thrombosis and 
regulating neointimal hyperplasia has led to restcnosis 
prevention strategies that focus on enhancing endo- 
thelialiazation.2,14,17,23 Novel stent coating strategies 
include delivery of vascular endothelial growth factor 
(VEGF) (e.g., VEGF-eluting stents37) and the use of 
antibodies that recognize epitopes specific to endo­
thelial cclls (e.g., anti-CD34-coatcd stents24). I lowever, 
these noncytotoxic approaches are still at the investi­
gational stage and their long-term outcome is 
unknown. Drug-eluting stents currently on the market, 
in contrast, release cytotoxic drugs to inhibit nco- 
intimal hyperplasia at the expense of delaying 
cndothclialization.25
Understanding the molccular details o f cell-matrix 
interactions that are involved in the development and 
maintenance of patent vessels may facilitate the dis­
covery of novel approaches to improve intracoronary 
stents. This study aimed to better understand clastin- 
endothelial interactions and explore the potential of 
elastin as a coating material for intravascular dcvices. 
Elastin is a predominant vascular extracellular matrix 
protein and plays an important structural and signal­
ing role in the development of patent arteries.32 Elastin 
is synthesized from soluble tropoelastin which is 
organized into clastic fibers with contributions 
from fibrillin microfibrils30 and glycoproteins such as 
fibulin-5.27,34’35 These fibers form concentric elastic
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lamellae around vascular lumens, providing the elas­
ticity necessary to absorb and distribute mechanical 
stress during the cardiac cycle.
Despite the close proximity of endothelial cells to 
the internal clastic lamina, there have been only a few 
conflicting studies investigating the molecular details 
of elastin—endothelial interactions. Coacervatcd alpha- 
clastin has been shown to have a dose-dependent cffcct 
on porcine aortic endothelial cell proliferation and 
migration,18’19 while studies using human umbilical 
vein endothelial cclls reported that adsorbed tropoe- 
lastin on plastic promoted cell adhesion but not cell 
spreading40 and covalcnt immobilization of tropoc- 
lastin on plasma-treated metal surfaces promoted cell 
adhesion and proliferation.'41 The variability in elastin 
cffcct in these studies may be due to specific domains 
of tropoclastin and their corresponding endothelial cell 
surface receptors, which remain to be explored.1" At 
least two ccll adhesive sites have been identified on 
tropoclastin: the hcxapcptidc VGVAPG sequence, 
which is loeated in the middle of tropoclastin, and the 
carboxyl terminus of tropoclastin. Multiple clastin- 
binding proteins targeting the VGVAPG sequence 
have been identified and include a 59-kDa protein,5 a 
67-kDa galactosidc-binding protein,15 a 120-kDa 
protein callcd elastonectin,16 and an unidentified 
Gr linkcd G protein-coupled receptor (GPCR).20 The 
carboxyl terminus of tropoclastin binds to ccll surface 
glycosaminoglycans7 and the heterodimeric intcgrin 
l y f t ' ' ’'4 Detailed studies of clastin-cell interaction 
studies have focuscd on vascular smooth muscle 
cells, fibroblasts, and cancer cclls, but not endothelial 
cells.
In this study, we compared the stimulating cffcct of 
recombinant tropoelastin on migration and adhesion 
of endothelial and smooth muscle cclls. We also 
investigated whether the biological activity of tropoc­
lastin on endothelial cclls is contained in the VGVAPG 
domain and the carboxy-terminal 17-amino acids, as 
well as determining the type of receptors which bind 
each of these domains. Finally, we examined endo­
thelial functionality (reaching confluence; adhesion 
and retention under flow) on metal surfaces coatcd 
with covalently immobilized tropoelastin. Our findings 
suggest that tropoclastin coating is a promising 




A 48-wcll Boyden chambcr apparatus and 
8 /(m-pore polycarbonate membranes for migration
experiments were from NeuroProbe (Cabin John, MD, 
USA). Type I collagen (CN) and fibronectin (FN) were 
from Biomcdical Technologies (Stoughton, MA, 
USA). Monoclonal anti-integrin antibodies [mouse 
anti-human (clone LM109) and mouse-anti-
human y.2ji\ (clone BHA2.1)] were from Chemicon 
International (Temecula, CA, USA). Purified whole 
mouse IgG was purchased from Jackson Immuno- 
Research Laboratories (West Grove, PA, USA). 
Oregon Green 488-conjugatcd phalloidin and DAPI 
nuclcar counterstain were purchased from Molccular 
Probes/Invitrogen (Carlsbad, CA. USA) and Vector 
Labs (Burlingame, CA, USA), respectively. Bovine 
scrum albumin (BSA) and acetylatcd 1% gelatin from 
porcinc skin was purchased from Sigma (St. Louis, 
MO, USA). Other chemical reagents and ccll culture 
ware/reagents were purchased from Fisher Scicntific 
(Pittsburgh, PA, USA) and Lonza (Walkersvillc, MD, 
USA), respectively, unless otherwise mentioned.
Recombinant Human Tropoelastin and Synthesized 
Elastin Peptides
The endogenous signal scqucncc of human tropo­
clastin (tELN) was removed and rcplaccd with a 
10 x -histidine tag. This cDNA was eloned into an 
isopropyl-/?-D-thiogalactosidc (IPTG)-induciblc con­
struct using the pET System and then expressed in the 
Escherichia colt host strain Rosetta-2 (DE3) pLysS 
(Novagen/EMD Bioscicnces, San Diego, CA, USA). 
LB growth media containing 50 ;ig/mL ampicillin and
34 /Jg/mL chloramphenicol were inoculated with 
Rosetta-2 (DE3) pLysS bacteria containing the 
recombinant tropoelastin plasmid, and the culture was 
grown at 37 °C until OD at 600 nm =  0.4-0.6. 
Induction was accomplished by adding IPTG to a final 
concentration of 1 mM. The culture was incubatcd at
37 °C for 4 h. The bacterial pellet was harvested by 
compounding centrifugation and weighed. The pellet 
was processed in Bugbuster HT + lysozyme (Nova­
gen), and inclusion bodies were purified according to 
Novagen’s protocol. Following the last wash, the 
inclusion bodies were pelleted and dissolved overnight 
at 4 °C in Ix  Bind Buffer (500 mM NaCI, 20 mM 
Tris-HCI, 5 mM imidazole) containing 6 M urea, pH 
7.9. Insoluble material was then removed by centrifu­
gation. The supernatant was filtered through a 0.45-/tm 
syringe filter. The sample was then added to His-Mag 
beads (Novagen) that had been prc-cquilibratcd to 1 x 
Bind Buffer with 6 M urea. Beads were collcctcd using 
a Magnatight stand (Novagen) and washed four times 
with wash buffer (500 mM NaCI, 60 mM imidazole, 
20 mM Tris-HCI) containing 6 M  urea, pH 7.9. 
The recombinant tELN protein was eluted from the 
beads with 500 mM imidazole, 500 mM NaCI, 20 mM
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Tris-HCl, 6 M urea, pH 7.9. The sample was dialyzcd 
against 11BSS using Slidc-A-Lyzer Dialysis Cassettes 
with 10,000 MWCO (Pierce). Purified protein was 
analyzed by SDS-PAGE analysis by standard tech­
niques and stored at —80 °C. Elastin-derived peptides 
[VGVAPG and IFPGGACLGKACGRKRK (Cterm 
peptide)] were synthesized at the DNA/Peptidc Facility, 
University o f Utah.
CD 34 + Cell Purification
Human CD34 + cells were purified from a periph­
eral blood mononuclear ccll preparation collcctcd by 
an aphcresis procedure. The donor was mobilized with 
10 jig/kg granulocyte colony-stimulating factor for 
4 days prior to the collection procedure, as approved 
by the Institutional Review Board of the University of 
Utah. Purification of CD34 + cclls was accomplished 
in a closed and sterile system using an automated 
cell selection device, CliniMACS (Miltcnyi Biotec, 
Auburn, CA, USA), following manufacturer’s instruc­
tions. 98% CD34 + cclls were obtained by flow cytome­
try using a FACScan analyzer (Becton-Dickinson, 
San Jose, CA, USA) and 1SIIAGE protocol.36
Endothelial Cells, Routine Cell Culture, 
and Preparation for Experiments
Human aortic endothelial cclls (HAEC), human 
coronary artery endothelial cclls (HCAEC), human 
microvascular endothelial cells (HMVEC), and 
human aortic smooth muscle cells (HASMC) were 
purchased from Lonza and eultured according to 
manufacturer’s specifications in Endothelial Growth 
Medium-2 (HAEC), Endothelial Growth Mcdium- 
2MV (HCAEC, HMVEC), or Smooth Musclc Grow'th 
Medium-2 (HASMC). Low passage cclls (2-7) were 
used in all experiments. Sixteen hours prior to experi­
ments, cultures were serum-starved using basal med­
ium [Endothelial Basal Mcdium-2 (EBM-2) for EC: 
Smooth Musclc Basal Mcdium-2 (SmBM-2) for SMC] 
and 0.5% fetal calf serum.
Migration Assays
Migration assays were performed as described/1’28’-15 
In brief, HAEC were lifted, diluted in buffer (0.5% 
BSA in EBM-2) to 1.5 x 106 cells/mL, and recovered 
in suspension at 37 °C and 5% C 0 2 for 1 h. For 
inhibition assays, 25 /(g/niL anti-ay/^ antibodies or 
control IgG were added to the ccll suspension during 
the recovery period. All migration assays were per­
formed in the 48-well Boydcn chamber apparatus.
30 fiL o f recovered cclls (4.5 x 104 cclls total) was 
added to the bottom chambers, and the wells were
overlayed with an 8 /tm-porc polycarbonate membrane 
coatcd with 1% acetylatcd gelatin. The apparatus was 
assembled and inverted for a 2-h period at 37 °C and 
5% C 0 2. The apparatus was then re-invcrtcd, and 
52 /fL of 0.1% BSA in DMEM (diluent, random 
migration control) or chcmoattractants [10 ng/mL 
fibroncctin (positive control), 10-200 ng/mL tropoe- 
lastin, 10 fiM  VGVAPG, and 10/iM IFPGGAC 
LGKACGRKRK Cterm peptide] were added to the 
upper chambers. Migration was allowed to procccd for
2 h at 37 °C and 5% C 0 2 in an incubator. Membranes 
were then removed, fixed in methanol, and stained with 
Hcma 3. Non-migrated cclls were removed from the 
membrane with a moistened swab, and membranes 
were mounted migratcd-sidc down on glass slides. The 
number of cells migrating through the membrane per 
high power field (HPF) on a Zeiss Axiovert 200 
inverted microscopc equipped with a Zeiss Axiocam 
digital camera was recorded. Two HPFs were observed 
for each well and averaged for each independent sex- 
tuplicate-wcll set. Final results were expressed as the 
average number of cells per HPF from three or more 
independent experiments.
Adhesion Assays on 96-lVell Plates
Adhesion assays were performed as described8’22 
with minor modifications. 96-wcll plates were coatcd 
overnight at 4 °C with 10 /ig/mL collagen type I, 
fibroncctin, tropoelastin, or 0.1% BSA, and then 
blockcd for 1 h at 25 °C in 5% BSA. HAEC were lifted 
from T-75 flasks, diluted in buffer (0.5% BSA in EBM-2), 
and recovered in suspension at working density 
(5 x 105 cells/mL) at 37 °C and 5% C 0 2 in an incu­
bator for 1 h. For inhibition assays, 25 /(g/niL anti- 
a2P\ antibodies, anti-ayfe antibodies, or control IgG 
were added to the cell suspension during the recovery 
period. 100 fiL of recovered cclls (5 x 104 cells total) 
was added to the coated wells, and adhesion was 
allowed to proceed for 30 min at 37 °C and 5% C 0 2 in 
an incubator. Following this incubation, the plates 
were inverted and washed twice with phosphate buf­
fered saline (PBS) to remove non-adherent cclls. Wells 
were then fixed in Zamboni fixative, stained with Gill 1 
hematoxylin, overlayed with 80% glycerol, and imaged 
at lOOx magnification on a Zeiss inverted microscope. 
The number of adherent cclls was averaged for two 
wells (duplicate) in each independent experiment. Final 
results were expressed as the average number of cells 
per well from three or more independent experiments.
Adhesion Assays on Stainless Steel Disks
Adhesion assays using unmodified 6 mm stainless 
steel disks or disks modified with anti-CD34 antibody.
8340 W ils o n  et a l
tropoclastin, or polysaceharidc base matrix as vchiclc 
control (provided by OrbusNeich Medical, Fort Lau­
derdale, FL, USA) were performed as described above 
with the Following modifications: 48-well plates were 
used, and twice the number/volume of cells (10s cells in 
200 /iL) was added to each well. Adhesion was allowed 
to proceed for 30 min at 37 °C and 5% C 0 2. Post­
adhesion, the wells were washed in PBS, fixed in 4% 
neutral buffered formalin, pcrmeabilized in 0.5% Tri­
ton X-100 (PBS), blocked in 5% non-fat milk (PBS), 
and stained for actin fibers with Oregon Green 488- 
conjugatcd phalloidin. Disks were mounted on modi­
fied microscope slides with Vectashicld mounting 
medium + DAP1 (Vector Labs) and imaged using a 
Zeiss fluorescent microscope. The numbers of adherent 
cells were countcd and final results were expressed as 
the average number of cells per disk.
Spinning Disk Adhesion Strength Assay
22-mm round glass coverslips were coated with 
tELN, FN, anti-CD34 antibodies (Santa Cruz), or 
BSA for 2 h at room temperature in 6-wcll plates. 
3 mL o f 5 x 104 IIAEC/mL in EGM2 was then 
added to each well and cells were allowed to adhere for 
6 h at 37 °C and 5% C 0 2. After 6 h, coverslips were 
inverted and submerged in HEPES-BSS on a custom 
holder at 37 °C and spun at 2100 RPM for 5 min as 
previously described.12 After 5 min, coverslips were 
removed and immediately fixed and mounted on slides 
with Vectashicld mounting medium + DAP1 and 
imaged using a BD Pathway 855 microscope. The 
number of cclls/HPF at various distances from the 
center of the coverslip was countcd and expressed as 
the percentage of cells remaining compared to the 
center of the disk and normalized to static controls. 
The shear stress at each measurement location was 
calculatcd as described.12
Fluid Shear Stress Assays
HAEC were seeded onto 6-mm tropoclastin-coatcd 
stainless steel disks or controls (6 mm silicone disks 
coatcd w’ith fibroncctin) in 48-wcll plates as described 
above. Cells were allowed to grow to confluence on the 
disks for 48 h prior to subjection to flow. The disks 
were placed in flow chambers and exposed to 24 h of 
laminar arterial flow of 16 dyn/cm2 or static conditions 
utilizing a recirculating flow system.11’33 The disks 
were fixed and stained for actin using phalloidin as 
previously described, then mounted with Vectashicld 
mounting medium with DAPI and imaged. Images 
were processed for actin alignment using a custom 
Matlab program based on previously described image­
processing methods.142
Data Presentation and Statistical Analysis
Bar graphs represent the average of three or more 
independent experiments. Vertical error bars on data 
points represent the standard error o f the mean. The 
Student /-test and analysis of variance were used to 
determine the significance of differences between two 
conditions and between more than two conditions, 
respectively. p-Value less than 0.05 was considered 
statistically significant.
RESULTS
Tropoelastin Stimulates Endothelial CelI Migration
The entire length of tropoelastin is well conserved 
among human, bovine, and murine proteins with 
82.4% similarity across the length of the entire protein 
(Supplementary Fig. 1). Purified recombinant tropoe­
lastin has a molecular weight of -65 kDa and is free 
from significant contaminating proteins (Supplemen­
tary Fig. 2). Using a Boydcn chamber apparatus, we 
performed migration assays w'ith IIAEC and various 
concentrations of full-length recombinant tropoclastin. 
Compared to the BSA control, there was a significant 
increase (4.5-fold) in endothelial migration using 
tropoclastin doses as low as 10 ng/mL (Fig. la). At 
200 ng/mL there was an eightfold increase that was 
comparable to the effect of 10 ng/mL VEGF. In order 
to differentiate chemokinesis versus chemotaxis, we 
also performed the experiment using equivalent trop­
oclastin concentrations in the upper and lower Boydcn 
chambers and observed no increased migration com­
pared to control, suggesting chcmotaxis rather than 
chemokinesis (data not shown). Similar results were 
seen with other endothelial cell types, including 
HMVEC and HCAEC (data not shown).
VGVAPG and the C’arhoxy Terminus o f  Tropoelastin 
Stimulate Endothelial Migration Through 
Different Mechanisms
We next compared the effect of another know'll 
endothelial chcmotaxis stimulant, fibroncctin, with the 
cffect of full-length recombinant tropoelastin and the 
clastin fragments VGVAPG and the Ctcrm peptide. 
Bccausc the carboxy terminus of clastin has been shown 
to bind the integrin y.vfii in solid-phase assays31 and 
recently in fibroblasts,4 we also investigated the 
involvement of av /?3 in this study using the u-vlh blocking 
antibody LM609. The isotype-matched control anti­
body IgG increased the baseline endothelial transwell- 
migration by twofold, perhaps by blocking the 
non-specific binding sites between the cells and the trans- 
wcll membrane.29 In the presence of IgG, each chcmotaxis
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FIGURE 1. Soluble recombinant tropoelastin stimulates 
migration ot HAEC through ditferent mechanisms, (a) HAEC 
migration toward 0.1% BSA, 10 ng/mL VEGF, o r 10-200 ng/mL 
tELN for 2 h in a 48-well Boyden chamber apparatus. * p<  0.05 
when compared to  the BSA control; * p<0,05 when compared 
to  10 ng/mL tELN. (b) HAEC pretreated with either noinspecific 
IgG or anti-xv/i3 antibodies were allowed to  migrate toward 
0.1% BSA, 10 ng/mL FN, 10 ng/mL tELN, 10 ,iM VGVAPG, or 
10 /iM IFPGGACLGKACGRKRK (Cterm) fo r 2 h. Migration w ith 
the Cterm peptide in the upper and lower chambers of the 
Boyden apparatus (C/C, last bar) was carried out to  differen­
tiate between chemokinesis and chemotaxis. * p <  0.05 when 
compared to  the BSA-IgG control; * p<0.05 when compared 
to  respective an ti- iv fo  treated samples; s p<  0.05 when com ­
pared to  Cterm-lgG.
stimulants caused a 2 to 2.5-fold increase in endothelial 
migration when compared to the BSA control (Fig. I b). 
The anti-av/?3 antibody almost completely inhibited the 
stimulating effect of fibronectin, full-length tropoclas- 
tin, and the Cterm peptide, as would be expected for 
processes that involve signaling through avf t .  I lowever, 
endothelial migration to VGVAPG (which may be 
mediated by an unknown GPCR21) was not affectcd by 
the anti-avf t  antibody. When the Cterm peptide was 
added to the upper and lower Boyden chambers 
(Fig. 1 b, last bar), there was no increased migration, 
indicating that this peptide promotes chemotaxis. The 
anti-av/>3 antibody had the same effect on tropoclas- 
tin and the Cterm peptide, suggesting that Cterm is 
sufficient for recapitulating the migratory response of 
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FIGURE 2. Adhesion of HAEC to  recombinant tropoelastin- 
coated plastic surface is mediated by j v/;3. Adhesion experi­
ments were carried out using 96-well plates pretreated with 
0.1% BSA, 10 /ig/mL collagen (CN), 10 /ig/mL fibronectin (FN), 
or 10 /ig/mL tELN. HAEC in suspension were pretreated with 
anti-x2pi or antibodies or non-specific IgG before being 
allowed to  adhere to  the protein-coated surfaces for 30 min. 
* p < 0.05 when compared to  the BSA-IgG control; * p<0.05 
when compared to  tELN-IgG; s p<0.05 when compared to 
tELN-3t2/fi-
Tropoelastin Promotes Endothelial Cell Adhesion 
Through otvp3
The adhesion of HAEC to wells pre-coatcd with 
0.1% BSA or with 10 /jg/mL collagen (also an 
integrin-binding protein), fibronectin, or tropoelastin is 
quantified and shown in Fig. 2. To determine the 
involvement of integrin in cell adhesion, I1AEC were 
incubatcd with either IgG control or anti-aj/^i or anti- 
«vft blocking antibodies prior to being exposed to the 
coated surfaces. In the presence of the IgG antibody, 
tropoelastin coating resulted in an approximately 
eightfold increase in endothelial adhesion compared to 
BSA coating; this amount of increased endothelial 
adhesion is similar in magnitude to the cfifect of 
collagen or fibronectin coating. Preincubation with 
anti-a2/#i or anti-oiv /?3 antibodies did not significantly 
decrease HAEC adhesion to fibronectin or collagen. 
This is likely explained by the fact that endothelial cells 
express multiple integrins that bind collagen or fibro- 
nectin.29 However, endothelial adhesion to tropoclas- 
tin was blocked by more than 50% by the anti-avft 
blocking antibody, '['his suggests that binding of 
tropoelastin to the integrin is the predominant 
mechanism for endothelial adhesion to tropoclastin- 
coatcd surfaces.
Tropoelastin Promotes Adhesion and Migration 
o f Endothelial and Smooth Muscle Cells 
to Different Degrees
Tropoelastin promotes the migration and spread­
ing of mouse aortic smooth muscle cells through a
10
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FIGURE 3. Effects of recombinant tropoelastin on stim ulat­
ing migration and adhesion of HAEC and HASMC. (a) HAEC 
and HASMC were allowed to  migrate toward 0.1% BSA, 
10 ng/mL FN, or 10 ng/mL tELN fo r 2 h in a Boyden chamber 
apparatus. The number of migrated cells was normalized to  
the 0.1% BSA-EC control. * p<0.05 when compared to  the 
BSA-EC control; * p<  0.05 when compared to  respective SMC 
samples; s p <  0.05 when compared to  the BSA-SMC samples, 
(b) Adhesion experiments were carried out using 96-well 
plates that were pretreated w ith 0.1% BSA, 10 /ig/mL CN, 
10 /<g/mL FN, or 10 jig/mL tELN overnight. HAEC and HASMC 
in suspension were allowed to  adhere to  the protein-coated 
surfaces fo r 30 min. The number of adherent cells was nor­
malized to  the 0.1% BSA-EC control. *p < 0 ,0 5  when com ­
pared to the BSA-EC control; *p < 0 .0 5  when compared to  
respective SMC samples; ® p<0.05 when compared to  the 
BSA-SMC samples.
non-integrin, G-protcin-couplcd signaling pathway.
In this study, we were interested in direct comparison 
of the stimulating effect of tropoelastin on the migra­
tion and adhesion of HAEC and HASMC. As shown 
in Fig. 3a, the baseline motility of HAEC is fivefold 
higher than that of 11ASMC. Both fibroncctin and 
tropoelastin increased the motility of HAEC and 
HASMC, but the motility of HAEC remained signifi­
cantly higher than HASMC. As shown in Fig. 3b, the 
baseline adhesion of HAEC was comparable to that of 
HASMC. While collagcn, fibroncctin, and tropoclastin 
promoted the adhesion of both cell types, their stim­
ulating effects for HAEC were significantly stronger 
than for HASMC.
Tropoelastin Covalently Linked to Stainless Steel 
Promotes Adhesion and Spreading o f  Endothelial Cells
The above results suggest that soluble tropoelastin 
promotes HAEC migration and that tropoclastin 
coating of plastic surfaces by adsorption promotes 
HAEC adhesion to those surfaces. In vivo endotheli- 
alization of intravascular dcvices presumably occurs 
through adhesion of circulating endothelial cclls 
and/or their progenitors, and through invasion of 
endothelial cells from the borders of the coatcd surface 
and/or from the vasa vasorum.9 To examine the effects 
of tropoclastin on adhesion and spreading of endo­
thelial cells on stainless steel, tropoclastin was cova­
lently immobilized to 6-mm diameter stainless steel 
disks (Fig. 4a) that were pre-treatcd with a stable 
polysaccharide base matrix (Ssens BV, Hcngclo, The 
Netherlands). Other disks were coatcd with anti-CD34 
antibodies or with polysaccharidc vchiclc alone. Cor­
onary stents coatcd with immobilized anti-CD34 
antibodies (Gcnous Bio-engineered R stent™ ) accel- 
cratc endothelialization by promoting the capture of 
circulating endothelial cclls and endothelial progenitor 
cclls.1 Adhesion experiments using human CD34 + 
cndothelial progenitor cclls, HAEC, and HMVEC 
(Fig. 4b) demonstrated a greater than ninefold increase 
in endothelial adhesion to disks coated with anti-CD34 
antibodies or tropoelastin over the vehicle control. 
Additionally, the tropoelastin coating increased the 
number of adherent IIAEC and HMVEC, but not 
CD34+ cclls, compared to the CD34 antibody-coated 
disks.
We next examined cell spreading on the coated 
metal surfaces by staining adherent cells with phalloi­
din to highlight the actin cytoskeleton and DAPI to 
mark ccll nuclci. Both CD34-antibody and tropoclas­
tin coating enhanced the adhesion of human CD34 + 
cclls and HAEC to the metal disks, though these cclls 
did not spread well on either coating within 30 min of 
adhesion (Fig. 4c, left and middle panels). In contrast, 
HMVEC adherent to tropoclastin-coatcd metal disks 
were well spread and demonstrated an organized actin 
cytoskeleton within 30 min of adhesion (Fig. 4c, lower 
right panel). 11AEC formed confluent monolayers on 
tropoclastin-coated metal disks when allowed to 
adhere for hours rather than minutes (Fig. 5b, left 
panel). Overall, these studies demonstrate that modi­
fying foreign surfaces with tropoclastin may stimulate 
endothelial spreading in addition to adhesion.
Cells Remain Adherent to Tropoelastin-CoatedSurfaces 
Under Fluid Shear Stress
Intravascular dcvices modified with tropoelastin 
would be exposed to physiological fluid shearing forces.
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FIGURE 5. Adherence o l endothelial cells to coated surfaces 
under conditions of flow, (a) HAEC adhered to  FN, tELN, BSA, 
or anti-CD34 antibodies (CD34 Abs) coated coverslips were 
exposed to  shear stress. + p<0.05 when com paring FN and 
BSA coatings; § p<0.05 when com paring tELN and BSA 
coatings; * p<0.05 when com paring FN and anti-CD34 Abs 
coatings; * p<0.05 when comparing tELN and anti-CD34 Abs 
coatings, (b) HAEC grown on tELN-coated d isks were stained 
with phalloidin (green) and DAPI (blue). Each panel depicts a 
representative fluorescent m icroscopic image, (c) Upper 
panels: Each panel depicts a representative HPF fluorescent 
m icroscopic image of actin cytoskeleton (green) and nuclei 
(blue). Lower panels: The directional alignment of actin fibers 
is shown using a ColorMap to  represent the local angle of 
each fiber. Cells under arterial flow  show an ordered and 
aligned cytoskeleton, as demonstrated by more uniform fiber 
coloration (higher levels of blue and purple). In contrast, cells 
under static conditions show sim ilar levels of all colors, 
indicating random alignment.
to align unidirectionally under arterial flow, as com­
pared to the random alignment of the static samples 
(Fig. 5c). The same cffcct was observed in the 11AEC 
monolayers on fibronectin-coatcd silicone disks (data 
not shown). This suggests that cells that attach to 
tropoclastin-coatcd intravascular dcvices remodel in 
response to flow, in addition to withstanding physio­
logical flow conditions.
DISCUSSION
Here, we propose a biomimctic approach for 
enhancing endothelial recovery: mimic the internal 
clastic lamina by coating intravascular dcvices with 
tropoclastin. T his approach capitalizes on the biolog­
ical properties of tropoclastin and does not require 
faithfully recreating the complex physical properties of 
clastic fibers. Thus, the need for protein production in 
mammalian expression systems or the use of clastic 
fibers extracted from animals is avoided.
We confirm that the biological activity of tropoe- 
lastin on endothelial cclls is contained in the VGVAPG 
domain and the carboxy-tcrminal 17-amino acids, and 
we provide evidence that the activity of the carboxy 
terminus is mediated via and appears distinct
from the effect of the hcxapcptidc VGVAPG. We 
demonstrate that recombinant tropoclastin stimulates 
endothelial cell migration and adhesion, and the cffcct 
is stronger for endothelial cells than smooth musclc 
cclls. Further, we show that tropoclastin coatings on 
metal surfaces (by covalcnt immobilization) enhances 
adhesion of endothelial progenitor cclls and several 
endothelial ccll types to the metal surfaces, and that 
endothelial cells can form confluent monolayers on the 
metal surface which resist and respond to arterial 
shear stresses. It is possible that the alignment of 
endothelial cells on tropoclastin may be mediated by 
ctyjii, which has been shown to mediate the effect of 
shear stress on endothelial cytoskeleton reorganization 
on fibronectin.1"1'"18
Tropoclastin has several potential advantages when 
compared to two other novel intravascular dcvice 
coatings, VEGF and anti-CD34 antibodies. The 
endothelial chcmotaxis stimulating effect of tropoe- 
lastin at 1.5 nM was comparable to the effect of 
VEGF at 0.5 nM. Thus, tropoclastin is similarly 
effective in attracting endothelial cclls but does not 
have the potent vascular permeability enhancing cffccts 
of VEGF which result in several well-documented 
adverse effects.6 Wc also show' that tropoelastin, while 
not as specific as anti-CD34 antibodies in its adhesive 
cffccts, has a strong pro-adhesive cffcct on endothelial 
cclls, and preferentially promotes the adhesion of 
endothelial cclls over non-cndothclial ccll types. 
Additionally, we show that the endothelial cells 
adherent to tropoclastin spread their cytoplasm and 
intracellular actin network to a greater degree than on 
anti-CD34 antibodies, as they might after adhesion to 
an intact internal elastic lamina in vivo. Cell spreading 
is critical as it is required for the effective coverage of 
the foreign surface and for the cclls to withstand fluid 
shearing forces. Thus, a potential advantage of trop­
oelastin coating is enhanced cell spreading, which is 
not cxpcctcd or observed in strategies that aim to
13
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capture endothelial cells using antibodies to ccll sur­
face markers. Indeed, our data show that cell retention 
under high fluid shear stress is better on tropoclastin 
than on anti-CD34 antibody-coated surfaces.
Stainless steel is a very common material in the 
construction of intravascular dcvices, and therefore is 
the focus of this study. It should be noted, however, 
that our experiments also included tissue culture 
plastic surfaces and silicone sheets, and tropoclastin 
performed similar to the results we described on 
stainless steel, suggesting that tropoclastin coating 
could be applicable as an intravascular dcvice coating 
on any number of other dcvice materials in use now or 
in the future. This study suggests that tropoclastin 
coating is a promising approach for enhancing endo- 
thelialization of intravascular dcvice, but further 
exploration is needed to determine the promise and 
practicality of accclcrating endothelialization by 
immobilizing tropoelastin to the surfaces of vascular 
devices cither alone or in combination with other drug 
eluting or coating strategies.
The online version of this article (doi: 10.1007/ 
sl0439-010-0142-z) contains supplementary material, 
which is available to authorized users.
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Supplementary Figure 1. Alignment of human, bovine, and murine tropoelastin amino acid sequences. The
hexapeptide VGVAPG is repeated 6 times (open boxes) near the mid-portion of human tropoelastin. The 17- 
carboxy-terminal amino acids (black box) of tropoelastin are well conserved in all three species (82.4% similarity). 
This carboxy-terminal region appears to mediate signaling through the integrin aV^ 3.
16
Supplementary Figure 2. SDS-PAGE analysis of purified recombinant human tropoelastin produced in 
bacteria. Following IPTG induction, whole cell lysates were prepared and electrophoresed on a 10% 
polyacrylamide gel, where the first column shows the standard protein markers (Std). In induced whole cell extracts 
(Ind), a band of expected molecular weight (arrow, ~65 kDa) was observed that was not seen in uninduced controls 
(Un). Isolation of bacterial inclusion bodies resulted in significant enrichment of recombinant protein. The last 
column shows that His-tagged human tropoelastin was purified to near homogeneity using nickel matrix binding 
and elution with imidazole.
CHAPTER 2
INTERLEUKIN RECEPTOR ACTIVATES A MYD88-ARNO-ARF6 
CASCADE TO DISRUPT VASCULAR STABILITY
The following chapter was reprinted with permission from Macmillian Publishers Limited. I was 
co-first author of this paper with Weiquan Zhu and Nyall R. London. In addition, the other authors were 
Chadwick T. Davis, Zongzhong Tong, Lise K. Sorensen, Dallas S. Shi, Jinping Guo, Matthew C.P. Smith, 
Allie H. Grossmann, Kirk R. Thomas, and Dean Y. Li. This article was originally published in Nature, 
2012 Dec;492:252-255. This manuscript details the role of ARF6, a small GTPase, in stabilization of the 




Interleukin receptor activates a MYD88-ARNO-ARF6 
cascade to disrupt vascular stability
W eiquan Zhu1,2*, Nyall R. London1,2,3*, Christopher C. Gibson2,4*, C hadw ick T. Davis2,5, Zongzhong Tong6, Lise K. Sorensen2, 
Dallas S. Shi2,5, Jinping Guo1'2,7, M atthew  C. P. Sm ith1,2,3, Allie H. G rossm ann2,8, K irk R. Thom as1,2 & Dean Y. Li1,2,3,9,10
The innate immune response is essential for combating infectious 
disease. Macrophages and other cells respond to infection by 
releasing cytokines, such as interleukin-l|i (IL-lp), which in turn 
activate a well-described, myeloid-differentiation factor 88 
(MYD88)-mediated, nuclear factor-KB (NF-kB)-dependent tran­
scriptional pathway that results in inflammatory-cell activation 
and recruitment1-4. Endothelial cells, which usually serve as a 
barrier to the movement o f inflammatory cells out o f the blood 
and into tissue, are also critical mediators o f the inflammatory 
response5,6. Paradoxically, the cytokines vital to a successful immune 
defence also have disruptive effects on endothelial cell-cell inter­
actions and can trigger degradation of barrier function and dis­
sociation of tissue architecture7 9. The mechanism of this barrier 
dissolution and its relationship to the canonical NF-kB pathway 
remain poorly defined. Here we show that the direct, immediate 
and disruptive effects o f IL-ip on endothelial stability in a human 
in vitro  cell model are NF-kB independent and are instead the 
result o f signalling through the small GTPase ADP-ribosylation 
factor 6 (ARF6) and its activator ARF nucleotide binding site 
opener (ARNO; also known as CYTH2). Moreover, we show that 
ARNO binds directly to the adaptor protein MYD88, and thus 
propose MYD88-ARNO-ARF6 as a proximal IL-ip signalling 
pathway distinct from that mediated by NF-kB. Finally, we show 
that SecinH3, an inhibitor o f ARF guanine nucleotide-exchange 
factors such as ARNO, enhances vascular stability and significantly 
improves outcomes in animal models o f  inflammatory arthritis 
and acute inflammation.
A defining characteristic of the cytokine-induced inflammatory 
response is the destabilization of endothelial barriers resulting in vas­
cular permeability7' 9. To dissect the pathway(s) involved in this tissue 
disruption, we treated cultured monolayers of human dermal micro- 
vascular endothelial cells (HMVEC-d) with IL-ip, and detected an 
increase in endothelial permeability within 15 min (Fig. la). The 
canonical IL-lp pathway involves ligand-stimulated activation of 
interleukin-1 receptor (IL-1R), which recruits MYD88 to its cytoplas­
mic tail10. The subsequent signalling cascade through IRAKI results in 
the phosphorylation of IkB-cx by the IkB kinase (IKK) complex, lead­
ing to translocation of NF-kB to the nucleus and the eventual tran­
scription of target genes that promote inflammatory-cell responses3,4 
(Supplementary Fig. 1). To test the involvement of this pathway in IL- 
lp-induced vascular permeability, cells were treated with the IKK 
inhibitor SC-514 (ref. 11). Although SC-514 prevented IL-1(3-induced 
nuclear localization of NF-kB, it was unable to rescue either IL-iP- 
induced permeability or disruption of vascular endothelial (VE)- 
cadherin surface localization (Fig. lb, c and Supplementary Fig. 2a-c). 
We also wondered whether IL-1 p-induced vascular permeability required 
other known MYD88-mediated downstream signalling mechanisms,
including ERK1/2, p38 and JNK (also known as MAPK3/MAPK1, 
MAPK14 and MAPK8, respectively)12,13. Although ERK1/2, p38 and 
JNK were activated by IL-1P stimulation of endothelial cells, small- 
molecule inhibitors of each of these pathways were unable to prevent 
IL-iP-induced vascular permeability or IL-iP-induced disruption 
of VE-cadherin cell-surface localization (Supplementary Fig. 2d-h). 
Although specific NF-kB targets, such as VEGFA, COX-2 (also known 
as PTGS2) and the COX-2 product prostaglandin E2 are modulated by 
IL-ip, their activation had no effect on IL-1 p-induced endothelial 
permeability3,14,15 (Supplementary Fig. 3a-e). Finally, treatment with 
actinomycin D or cycloheximide effectively inhibited transcription or 
translation, respectively, of NF-kB targets, but did not blunt IL-1 p- 
induced permeability (Fig. Id and Supplementary Fig. 3f, g). These 
data strongly support a role for the immediate and destabilizing effects 
of IL-1 P on endothelial stability through signalling pathways inde­
pendent of NF-kB, transcription and translation.
IL-1 (3 can disrupt VE-cadherin cell-surface localization by promo­
ting endocytic internalization9. We proposed that IL-lp might use 
ARF6, a known regulator of adherens protein localization16,17. 
Indeed, IL-lp activated ARF6 in HMVEC-d within 1 min, a response 
accompanied by increased endocytosis of VE-cadherin within 5 min 
and an increase in monolayer permeability within 15 min (Fig. la, e 
and Supplementary Fig. 4a, b). IL-1 p treatment did not affect total VE- 
cadherin messenger RNA or protein levels (Supplementary Fig. 4c, d). 
Adenoviral-mediated overexpression of constitutively active ARF6 
(ARF6(Q67L))1S elicited a dose-dependent increase in endothelial per­
meability, as well as a disruption of VE-cadherin cell-surface locali­
zation (Fig. If, g and Supplementary Fig. 4e, f). A similar dose- 
dependent loss of total VE-cadherin was also observed, probably 
through internalization and subsequent degradation (Supplementary 
Fig. 4g). Interestingly, at lower doses of adenovirus at which permea­
bility was still induced, loss of total VE-cadherin was not observed, but 
a dose-dependent loss of cell-surface VE-cadherin occurred (Fig. lf-h  
and Supplementary Fig. 4g), Moreover, short interfering RNA 
(siRNA) knockdown of ARF6 enhanced VE-cadherin cell-surface 
localization and prevented both IL-1P-induced disruption of VE- 
cadherin and IL-lp-induced endothelial permeability (Fig. l i-k  and 
Supplementary Fig. 4h, i). Collectively, these data link ARF6 as a 
critical regulator of VE-cadherin trafficking by controlling cell-surface 
localization and the immediate and disruptive effects of IL-1 p-induced 
vascular permeability.
The ARF6 activation state is decreased through interaction with 
GTPase-activating proteins (GAPs) and increased through interaction 
with guanine nucleotide-exchange factors (GEFs). Consistent with 
this, treatment of endothelial cells with the ARF-GAP inhibitor 
Q Sll evoked an increase in ARF6-GTP, a decrease in VE-cadherin 
cell-surface localization and increased permeability (Fig. 2a-d and
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Chronic inflam m ation causes tissue destruction through dysregu- 
lated cytokine release* inflam m atory cell recruitm ent and  vascular 
permeability; yet each o f  these m echanism s has critical roles in many 
physiologic processes, including the im m une response5,7. W e have 
identified a novel pathway that uncouples cytokine effects on  vascular 
stability from other critical functions o f the canonical N F-kB tran ­
scription program  (Supplem entary Fig. 1), O ur model suggests the 
potential for inhibition o f vascular leak w ithout m odulation  o f 
im m une-cell adhesion or o ther critical NF-KB-dependent responses.
The activation o f m any inflam m atory cytokine receptors disrupts 
cell-cell interactions, precipitating tissue oedem a and destruc- 
tion5’7,9’27. Toll-like receptors and the interleukin receptor also use 
MYD88, and  the m echanism  described here m ay well apply3,10. 
Interestingly, TNFR1 (also know n as TNFRSF1A) does no t use 
MYD88 yet still activates ARF6-G TP after stim ulation (Supplem en­
tary Fig. 9). W hether ARNO or another ARF-GEF binds directly to 
TNFR1 o r its adaptor protein TRADD is unknow n, as is the possibility 
that ARF-G EF-A RF6-cadherin serves as a com m on signalling m o­
dule exploited by m ultiple cytokines. A lthough this study focused on 
the endothelium , the concept o f cytokine receptor-A R F-cadherin 
m ay also apply to the epithelial barrier, which expresses these consti­
tuents and is also com prom ised by cytokines including IL -ip 16.
Inhibition o f this novel vascular-stability pathway, which is aim ed at 
enhancing the resilience o f the host to  the cytokine response, shows 
effects com m ensurate to  those o f class-leading drugs that target cyto­
kines upstream  o f N F-kB and seek to blunt the cytokine response o f 
the im m une system outright. This approach m ay be particularly useful 
in arthritis, as the curren t medical therapy can render a patien t im m u­
nocom prom ised and susceptible to reactivation o f infectious disease 
such as tuberculosis28. Application o f  these findings to o ther diseases 
characterized by excessive acute o r chronic inflam m atory states, 
including sepsis, C rohn’s disease, ulcerative colitis, scleroderm a and 
psoriasis, should also be considered9'29,30.
METHODS SUMMARY
Transwell permeability. HMVEC-d cells were seeded on 1.0-fim Costar transwell 
inserts coated with fibronectin. Cells were grown to confluency and treated with 
SecinH3 for 3 h or MAPK/NF-KB/transcription/translation inhibitors for 30 min 
followed by treatment with 10 ng ml-  IL-1 p. Alternatively, cells were infected with 
Ad-GFP or Ad-ARF6(Q67L) for 48 h. siRNA knockdown was performed as 
described in Supplementary Methods, and cells were treated with IL-1(3 72 h after 
the second siRNA transfection. T wo hours later, HRP was added to the top chamber 
at a final concentration of 100 |ig ml-  . Medium was removed after 60 min from the 
lower chamber. For time-course transwell assays and transcript ion/translation- 
inhibitor experiments (Fig. la, c, d), HRP was added to the insert at the same time 
as IL-1 p. Transwell inserts were moved to fresh wells after each time point, and the 
concentration of HRP in the bottom chamber was measured for monolayer per­
meability. HRP was assessed using media samples obtained from the lower chamber 
incubated with 0.5 mM of guaiacol and 0.6 mM H20 2. Spectrophotometric analysis 
of absorbance at 490 nm provided a quantitative evaluation of the amount of HRP 
that crossed the membrane. Data are presented as mean ± s.e.m. of at least three 
independent experiments performed in quadruplicate.
A detailed description of all methods is provided in Supplementary Information
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Supplementary Figure 1. Proposed IL lp signaling pathways.
IL-ip activates NF-kB through a MYD88-IRAK-lKB-dependent pathway. MYD88 also binds to ARNO, and through 
a divergent pathway enhances ARF6-GTP, and decreases VE-cadherin cell surface localization.
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Supplementary Figure 2. IL-ipinduced permeability is independent of NF-kB, ERK1/2, JNK, and p38.
(a) HMVEC-D cells were stimulated with IL-lp in the presence of DMSO or SC-514 and subjected to immuno­
fluorescence for NF-kB (green). White arrows indicate nuclear NF-kB. (b) HMVEC-D cells were stimulated with 
IL-lp in the presence of DMSO or the NF-kB inhibitor, SC-514. Transendothelial resistance was measured by Elec­
tric Cell-substrate Impedance Sensing (ECIS). (c) Quantification of IL-ip-induced disruption of plasma membrane 
VE-cadlierin treated with DMSO and SC-514 as shown in Figure lc. (d) Lysates from HMVEC-D cells stimulated 
with IL-lp in the presence of DMSO, U0126, SB203580 or JNK Inhibitor II were subjected to immunoblotting for 
p-ERKl/2, p-P38, or p-JNK. (e) Transwell permeability of HMVEC-D cells stimulated with IL-lp in the presence 
of inhibitors of ERK1/2 (U0126), P38 (SB203580), and JNK (JNK Inhibitor II). (f) Transendothelial resistance was 
measured by ECIS in HMVEC-D cells treated with IL-ip in the presence of DMSO, ERK1/2 inhibitor U0126, P38 
inhibitor SB203580, or JNK Inhibitor II in EGM2-MV complete media, (g) VE-cadherin immunofluorescence of 
HMVEC-D cells treated with IL-lp in the presence of DMSO, U0126, SB203580, or JNK Inhibitor II. White arrows 
indicate areas of reduced VE-cadherin surface localization, (h) Quantification of (g). For all experiments, N > 3 and 
error bars represent SEM. * p<0.05, ** p<0.01, *** p<0.001.









S U P P LEM EN T A R Y  INFORM ATION
METHODS 
Reagents
Human dermal microvascular endothelial cells (HMVEC-D) were purchased at passage 0 from 
Lonza and used at passages 2-6. SecinH3, ERK1/2 signal pathway inhibitor (U0126), P38 signal 
pathway inhibitor (SB203580), JNK signal pathway inhibitor (JNK Inhibitor II), and NF-kB 
signal pathway inhibitor (SC-514) were from Calbiochem. QS11 was from Sigma. Rabbit anti- 
VE-cadherin antibody, rabbit anti-MYD88 antibody (#3699 for western blot, #4283 for 
immunoprecipitation), rabbit anti-IRAKl antibody, rabbit anti-p-ERKl/2, rabbit anti-p-P38, 
rabbit anti-p-JNK antibody, rabbit anti-ERKl/2, rabbit anti-P38 antibody, rabbit anti-JNK 
antibody and rabbit anti-NF-KB P65 antibody were from Cell Signaling. Mouse anti-ARF6 
antibody was from Millipore. Mouse anti-ARNO antibody was from Abnova. ARF6  siRNA, 
ARNO  siRNA, MYD88 siRNA and IRAKI siRNA were from Qiagen.
Transfection and siRNAs
siRNAs were diluted in 12.5% HiPerFect Transfection Reagent (Qiagen) in Optimem 
(Invitrogen) and incubated 10-20 minutes at room temperature. As siRNAs were sitting, passage 
3-4 HMVEC-D cells were passaged and resuspended in EGM2-MV (Endothelial Cell Basal 
medium-2 supplied with EGM®-2 MV SingleQuots®, Lonza) and combined with siRNAs such 
that the final concentration of siRNA was 30nM (all targets). The cells were plated, allowed to 
grow overnight and then the growth media was replaced. Three days after the initial transfection, 
the cells were transfected a second time using the same HiPerFect/siRNA concentrations as 
above.
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The following is a table of all siRNAs used, their catalogue numbers, sequence, the location 
within the gene the siRNA targets, and average knockdown observed by western blot.
Gene Catalogue
Number
Target sequence (5’-3’) Region Mean
knockdown
ARF6 SI02757286 CAACGTGGAGACGGTGAC’TTA exon 77%
ARNO SI00061299 CACGCTGTTGGTAATCTTATT 3’ UTR 63%
Cytohesin-1 SI04217185 CGGGACAGAGGTTC’CGGATAA 3’ UTR 93%
Cytohesin-3 SI00061257 CAGCATGTTGTGCTCGGACAA 3’ UTR 99%
MYD88 SI00300909 AACTGGAACAGACAAACTATC exon 87%
IRAKI SI00605262 CCGGGCAATTCAGTTTCTACA exon 83%
Protein expression constructs
The coding sequence of full-length MYD88 (BC023589), ARNO  (BC038713), CYTH-1 
(BC038385), CYTH-3 (BC028717) and GEP100 (BC010267) were amplified by PCR from 
IMAGE cDNA clones and ligated into a pcDNA3.1 vector after enzyme digestion. The ARNO, 
CYTH-1, CYTH-3 and GEP100 constructs contained both MYC and HIS epitopes, while the 
MYD88 construct contained an HA epitope.
Subcellular fractionation
Subcellular fractionation was performed as previously described9. Briefly, HMVEC-D cells 
were infected with adenovirus for 48 hours, stimulated with Q S11 for 3 hours, or stimulated with 
SecinH3 for 2 hours. Alternatively, cells were transfected with siRNA as described above. The 
monolayer was washed two times with ice-cold phosphate-buffered saline (PBS) containing Ca2+ 
and Mg2+, and then washed a third time with HLB buffer [Tris-HCl lOmM at pH 7.4, KC1 5mM,
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protease inhibitors (Roche) and phosphatase inhibitors (Sigma), and dithiothreitol lmM], After 
the third wash, cells were homogenized in a Dounce homogenizer using 20 strokes. The 
homogenate was then centrifuged at 400g for 10 minutes at 4°C. The supernatant was subjected 
to centrifugation again at 16,000g for 30 minutes at 4 C. The pellet was washed with HTB 
buffer and resuspended in radioimmunoprecipitation assay (RIPA) buffer for 30 minutes at 4°C. 
The resuspended pellet was centrifuged at 16,000g for 15 minutes at 4°C, and the supernatant 
was saved as a soluble membrane fraction. To obtain the total cell lysate, an aliquot o f cellular 
material was set aside before Dounce homogenization. RIPA buffer was added to this aliquot 
and then the mixture was centrifuged at 13,000g for 10 minutes at 4°C, The resulting 
supernatant was saved for use as total cell lysate. Densitometry was performed on at least three 
independent experiments and data are presented as mean ± SEM.
ARNO Rescue Experiment
Cells (l.OxlO6 in a 10 cm dish) were first transfected with ARNO  siRNA (SI00061299, Qiagen) 
at 30nM and changed to fresh media 24 hours after the transfection. The siRNA was directed 
against sequences in the 3’ UTR of the endogenous ARNO  mRNA. 48 hours after the media 
change, cells were harvested and underwent a second transfection with the same siRNA at the 
same dose. Cells were then infected with either an Ad-ARNO (WT) or Ad-ARNO (E156K) virus 
(5*107 p.f.u.ml"1) 36 hours after the second siRNA transfection and incubated for 36 hours2. The 
adenoviral vectors expressing human ARNO (or mutant ARNO) fused to a MYC-epitope tag did 
not contain a 3 ;UTR ARNO  sequence, and was thus predicted to be resistant to the siRNA.
ARF6-GTP pull down assay: ARF6-GTP pull-down assays were performed as described21. 
Briefly, HMVEC-D cells were pre-treated with SecinH3 for 3 hours followed by treatment with
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lOng/mL IL-l(i. Alternatively, cells were transfected with siRNA as described above. Cells 
were treated with IL-ip 72 hours after the second siRNA transfection for 5 minutes. After 
treatment, media was aspirated and cells were rinsed with chilled Ultrasaline. Dishes were frozen 
on dry ice. Following thawing, ARF6 pulldown lysis buffer [Tris-HCl 50mM, NaCl lOOmM, 
M gCM mM , NP-40 1%, glycerol 10%, protease inhibitors (Roche) and phosphatase inhibitors 
(Sigma)] were added to cells. Lysates were centrifuged and supematants were added to GGA3- 
conjugated beads (Cell Biolabs, sta-40706), and agitated at 4°C for 60 minutes. Beads were 
washed in ARF6 pulldown lysis buffer and resuspended in 2X Laemmli prior to loading on 15% 
SDS-PAGE gels. A fraction of the cell lysate was withheld for use as a measure o f total ARF6 in 
each sample. Data are presented as mean ± SEM of at least three independent experiments.
Quantitative PCR
Lotal RNA was extracted from cells using the RNeasy plus mini kit (Qiagen) according to 
manufacturer’s instructions. RNA was converted to cDNA using RETROscript® kit (Ambion). 
Quantitative RT-PCR was performed using TaqMan probes (CYTH1, Hs00245092; ARNO, 
Hs00244669; CYTH3, HsOOl88456; CYTH4, Hs00203581; IQSEC1, Hs00208333; IOSF.C2, 
Hs00390333; IOSEC3, Hs01006522; EFA6A, Hs00160539; EFA6B, Hs00260268; EFA6C,
IIs00209633; A7vlrt«,l Is00202892; VEGFA, Hs00900055; ICAM I, Hs00164932; VCAM1, 
Hs01003372;IL-6, Hs9999032; IN Fa, HsOl 113624_gl; Cox2, Hs00153133; VE-cadherin, 
Hs00901463; E-selectin, HsOOl74057 m l)  and the ABI Prism 7900 HT Real-Time PCR System 
(Applied Biosystems). Quantification was performed using a human brain cDNA standard curve 
and normalized to 18S rRNA. Data are presented as mean ± SEM o f four duplicates from at least 
two independent experiments.
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Immunofluorescence
10,000 HMVEC-D cells were seeded onto 8 well chamber slides coated with human fibronectin. 
Cells were pre-treated with small molecule inhibitors o f NF-kB or MAPK for 30 minutes or 
Sccml 13 for 3 hours followed by treatment with 10 ng/ml IL -ip  for 2 hours. Alternatively, cells 
were infected with 1 105- 1 * 10s p.f.u.ml'1 o f the indicated adenovirus for 48 hours. For siRNA 
knockdown experiments, cells were harvested 72 hours after the first siRNA transfection, re­
transfected with the same siRNA a second time and seeded onto chamber slides. 72 hours after 
the second siRNA transfection, cells were treated with IL-1(3 for 2 hours. Cells were fixed, 
permeabilized, blocked with normal donkey serum and stained for VE-cadherin or NF-kB p65. 
The only exception to this protocol was for Supplementary Fig. 6f, where permeabilization was 
not performed in order to increase the signal o f cell-surface VE-cadherin. Images are maximum- 
Z-projections of confocal images acquired at 0.3 jjm z-section intervals. Image acquisition 
settings were identical for all images. Images are representative of at least 3 independent 
experiments. Quantification was performed using a custom Image-J macro that imported images, 
applied a threshold to exclude all but intensely-stained areas, and returned this area as an output. 
Identical threshold and size restriction values were used to analyze all images. Data are presented 
as mean ± SEM o f at least three independent experiments.
Immunoprecipitation
Immunopreciptation assays were performed as described9. Briefly, F1MVEC-D cells were 
treated with 10 ng/ml IL -ip  for 1 and 5 minutes. For Figure 3e, HMVEC-D cells were infected 
with 1 x 107 p.f.u.m l'1 Ad Null or Ad-ARNO-MYC 48 hours before IL-1J3 treatment. Cells were 
then washed with ice-cold PBS and lysed with ice-cold lysis buffer (Tris-HCl 50 mM, NaCl
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250mM, NP-40 1%, and glycerol 10% w ith protease inhibitors and phosphatase inhibitors). Cell 
lysates were centrifuged for 15 minutes at 13,000g and the supematants saved. A BCA assay 
(Pierce) was used to determine protein concentrations. Lysates were incubated with 8 mg of the 
indicated antibody and protein A/G-Sepharose (Santa Cruz Biotechnology) for 1 hour at 4°C.
Beads were then washed 5 times in lysis buffer. The immunoprecipitates were assayed by 
western blot analysis using Peroxidase-conjugated AffiniPure Light Chain Specific secondary 
antibody for signal detection. Data represents at least 3 independent experiments.
B i o t i n v l a t i o n  A s s a y
HMVEC-D cells were transfected with ARNO  siRNA or control siRNA and then infected with 
Ad null or Ad-ARNO (as described), and grown to 100% confluence on 100-mm dishes. Cells 
were washed with ice-cold PBS three times and labeled with EZ-link Sulfo-NHS-SS-Biotin 
(Thermo) at 0.5mg/ml in PBS for 30 minutes on ice. Excess Biotin was removed by washing 
with glycine in PBS two times on ice. The cells were then incubated with 10 ng/ml IL -lp  and 0.6 
mM Primaquine (MP Biomedicals) at 37°C for 30 minutes; they were then exposed to GSH 
buffer (Glutathione 50mM, NaOH 75mM, NaCl 75mM, EDTA ImM, BSA 0.1%, PH 9.0) on ice 
for 20 minutes to remove surface biotin. GSH was then quenched by washing with 5 mg ini 
iodoacetamide in PBS. After an additional wash with ice-cold PBS, cells were lysed in NP-40 
buffer (Tris-HCl 50 mM, NaCl 150 mM, MgC12 ImM, NP-40 1%, Glycerol 10%) with a 
protease inhibitor cocktail on ice. Cell lysates were centrifuged at 14,000 rpm for 15 minutes and 
supernatant was incubated with High Capacity Streptavitin Agarose Resin (Thermo) for 60 
minutes at 4°C. Beads were washed with NP-40 lysis buffer three times. Bound proteins were 
released in 2*Lacmmli buffer with 5% p-mercaptocthanol at 95°C and internalized VE-cadherin 
analyzed by immunoblotting with VE-cadherin antibody.
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Transendothelial resistance
Transendothelial resistance was measured by Electric Cell-substrate Impedance Sensing (ECIS). 
An 8W10E+ electrode culture array (Applied Biophysics) was coated with 10 ug/niL human 
fibronectin. 5 x 104 HMVEC-D per well were seeded in complete media onto the electrode 
culture array and monitored until a stable monolayer formed. A stable monolayer was indicated 
by a capacitance <10 nF at 6.4 x 104 Hz and a stable resistance over several hours at 4 x 10’ Hz. 
Cells were pre-treated with SecinH3/Avastin for 3 hours or MAPK/NF-kB inhibitors or 
Indomethacin or PGE2 for 30 minutes followed by treatment with 10 ng/ml I I - 1 |i (unless 
otherwise indicated). Alternatively, cells were infected with Ad-GFP or Ad-ARF6 (Q67L) 
adenoviruses. Resistance across the monolayer using alternating current at a frequency of 4 x 
10J Hz was measured by 40 electrodes per well (1000-2000 cells) using the ECIS-Z0 system 
(Applied Biophysics) and reported in Ohms or normalized to control treatment or initial 
resistance. Conditioned media was collected from cells undergoing ECIS (Supplemental Figure 
2e) at 16 hours after treatment with IT -1 |i in the presence of DMSO or inhibitors. PGE2 
concentration was calculated using the PGE2 Express EIA kit from Cayman Chemical (500141) 
according to manufacturer’s instructions. Data are representative o f at least 3 independent 
experiments or represented as mean ± SEM.
Transwell permeability
HMVEC-D cells were seeded 011 1.0 pm Costar transwell inserts coated with fibronectin. Cells 
were grown to confluency and treated with SecinH3 for 3 hours or MAPK/NF- 
KB/transcriptioa translation inhibitors for 30 minutes followed by treatment with lOng/ml IT.-11!. 
Alternatively, cells were infected with Ad-GFP or Ad-ARF6 (Q67L) adenovirus for 48 hours.
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siRNA knockdown was performed as described and cells were treated with IL -1 p 72 hours after 
the second siRNA transfection. Two hours later, horseradish peroxidase (HRP) was added to the 
top chamber at a final concentration o f lOOug. ml. Medium was removed after 60 minutes from 
the lower chamber. For time-course transwell assays and transcription/translation inhibitor 
experiments (Figure la , d), HRP was added to the insert at the same time as IL-1 (3. Transwell 
inserts were moved to fresh wells after each timepoint, and the concentration of HRP in the 
bottom chamber was measured for monolayer permeability. HRP was assessed using media 
samples obtained from the lower chamber incubated with 0.5 mM o f guaiacol and 0.6 mM H ;0 2. 
Spectrophotometric analysis o f absorbance at 490 nm provided a quantitative evaluation of the 
amount of HRP that crossed the membrane. Data are presented as mean ± SEM of at least three 
independent experiments performed in quadruplicate.
Fluorescence-Activated Cell Sorting (FACS)
FACS was performed as decribed31. HMVEC-D were pre-treated with SecinH3 for 3 hours and 
then stimulated with 10 ng/ml IL -1 p for 4 hours. Analysis o f the cell surface localization of 
adhesion molecules was performed with one step immunofluorescence staining using anti-hE- 
selectin-FITC, anti-hlCAM l-FITC and anti-hVCAM l-PE antibody (BD). Data are presented as 
mean ± SEM o f at least three independent experiments.
Leukocyte Rolling and Adherence assay
3 x 104 HMVEC-D were seeded into each well o f a fibronectin-coated parallel plate flow 
chamber (U-plate 0.4 VI Fibronectin, Ibidi GMBH). Media was changed daily using gentle 
aspiration until the cells had grown to confluence (approximately 3-5 days). Human 
polymorphonuclear leukocytes (PMNs) were isolated from whole blood according to previously
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described protocols32'33. Briefly, human peripheral venous blood (500 mL) from healthy, 
medication-free, fasting adult subjects was drawn into acid-citrate-dextrose (1.4 mL ACD/8.6 
mL blood) through standard venipuncture technique and used immediately upon collection. The 
University o f Utah Institutional Review Board approved this study and all subjects provided 
informed consent. Blood was centrifuged at 150 x g for 20 minutes at 20°C to separate platelet- 
rich plasma (PRP) from red and white blood cells (RBC/WBC). The PRP was removed and the 
remaining RBC/WBC mixture was resuspended in 0.9% sterile saline back to the original 
volume. A volume equaled to half the original blood volume o f 6% Dextran 70 (Sigma-Aldrich, 
St. Louis, MO) was then added to the RBC/WBC mixture and left for one hour. The leukocyte- 
rich supernatant was removed and centrifuged at 400 x g for five minutes a 4°C. The supernatant 
was then removed and the pellet resuspended (in 0.2% NaCl followed by an equal part o f 1.6% 
NaCl), and the cells were centrifuged at 400 x g for five minutes at 4°C. After centrifugation, the 
cells were resuspended in H ank's Balance Salt Solution (Sigma-Aldrich, St. Louis, MO) with 1% 
human serum albumin (HBSS/A) (University of Utah Hospital, Salt Lake City, UT) and layered 
over an equal volume of Ficoll-Paque Plus (GE Healthcare Biosciences, Piscataway, NJ). The 
layered cells were then centrifuged for 30 minutes at 400 x g at 4°C. After 30 minutes, the 
mononuclear leukocyte layer was removed, followed by the RBC layer, HBSS/A layer, and 
Ficoll-Paque layer. The remaining pellet containing greater than 95% PMNs was washed with 
HBSS/A and resuspended to 1 x 106 ml"1 in warmed ultrasaline (Lonza). Endothelial cells in 
parallel-plate flow chambers were pretreated with IL -lp  (10 ng/mL) and/or SecinH3 for 3 hours. 
A syringe pump (Harvard Apparatus) was used to flow the PMN solution through the parallel 
plate flow chambers at 1 dynes x cm’1 (a typical venous shear stress). Differential Interference 
contrast microscopy (DIC) images were taken once per second using an Olympus inverted
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microscope, and the total number of PMNs rolling and adhered in a 5 minute period were 
quantified using MetaMorph (Olympus) software. The data is presented as fold over IL-1 P 
induced leukocyte rolling ± SEM and represents three independent experiments, each consisting 
o f at least 3 replicates for each condition.
Internalization assay
VE-cadherin internalization assay was performed as previously described9. Briefly, HUVEC 
were transfected with siRNA as described above and seeded onto 8-well chambered coverglass 
at 5 x 104 cells/coverglass. After 72 hours, the culture was chilled at 4°C for 30 minutes, 
surface-labeled for 60 minutes on ice with 1 ug/mL dialyzed anti-VE Cadherin antibody (clone 
BV6, Millipore) in ice-cold labeling buffer (3% BSA in M CDB131 medium, Invitrogen). At the 
end of 60 minutes, the labeling buffer was removed and the cells were treated with 0.6 mM 
Primaquine plus vehicle or 10 ng/mL IL-ip , DMSO vehicle or 30 SecinH3 or 50 uM SC- 
514 for 15 minutes at 37°C and 5% C 02. Monolayers were washed 3 times over 10 minutes 
with ice-cold HBSS (HBSS - Hank's Balanced Salt Solution, Invitrogen) + 50mM Glycine + 3%
BSA, pH 2.7 to remove surface VE-cadherin. One well for each condition was washed in a 
neutral pH solution to retain surface VE-cadherin staining. Subsequently, monolayers were fixed 
immediately in 3% paraformaldehyde for 10 minutes. The VE-cadherin antibody was detected 
using an Alexa-Fluor 488 conjugated anti-Mouse IgG antibody and traditional 
immunofluorescence methods. To image the monolayers, five images per well were randomly 
selected using the DAPI channel at 600x. Z-series images were taken using a confocal Olympus 
F V 10001X81 microscope. Each treatment was done in triplicate. The assay score represents the 
average percentage of total cells in each image/well/treatment containing internalized VE- 
Cadherin,
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C o l l a g e n - i n d u c e d  a r t h r i t i s
Collagen-induced arthritis (CIA) studies were conducted by Washington Biotechnology using 
their standard procedures and DBA/1 J mice as previously published34'38. All protocols were 
approved by their IACUC (Institutional Animal Care and Use Committee) prior to initiation of 
the study. Six to seven week old male DBA/1 mice were used (Jackson Laboratories) with 5-20 
animals per group. Bovine type-II collagen (Chondrex) was dissolved in 0.01 M acetic acid, and 
an emulsion with 50 (il o f  Complete Freund’s Adjuvant was injected at the base of the tail at Day 
0. 21 days following the first injection, a booster injection consisting of a 50 (.il. emulsion of 
collagen in Incomplete Freund’s Adjuvant was injected at the base o f the tail. Arthritic index 
(Al) was scored for each limb of an animal as follows: 0 = no visible effects o f arthritis, 1 = 
edema and erythema of one digit or joint, 2 = edema and erythema o f two joints, 3 — edema and 
erythema of more than 2 joints, 4 = severe arthritis o f the entire paw and digits accompanied by 
deformity o f the limb. The score for each limb was summed, with 16 as the highest possible Al 
score for each animal. Treatments were either vehicle (0.5% DMSO/saline IP BID), SecinH3 
(0.1 mg/kg IP BID), or the positive control, Enbrel® ( 10 mg/kg SC OD). The experiment was 
repeated multiple times with different endpoints; detailed descriptions o f the exact timing for 
each experiment follow. In all cases, treatment was initiated after mild arthritis was established 
(therapeutic treatment).
EVAN’s BLUE DYE EXTRAVASATION: Treatment was initiated when the average arthritic 
index for each group was between 3 .4 -3 .5 5  and all mice in each group demonstrated a positive 
arthritic index. Due to the variation in when each group reached an average arthritic index of 3.4 
-  3.55, treatment initiation day varied from study day 28 (seven days after the second collagen 
injection) to study day 30 (nine days after the second collagen injection). The treatments lasted
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for seven days until the mice were sacrificed for the Evan’s Blue Dye Assay (described in detail 
in subsequent methods).
ARTHRITIS PROGRESSION: Treatment was initiated when the average arthritic index for 
each group was 3.1 and all mice in each group demonstrated a positive arthritic index. Due to the 
variation in when each group reached an average arthritic index o f  3.1, treatment initiation day 
varied from study day 28 (seven days after the second collagen injection) to study day 29 (eight 
days after the second collagen injection). The treatments lasted for 13 days in all groups with 
arthritic index recorded regularly throughout.
HISTOPATHOLOGIC PATTERNS: Treatment was initiated when the average arthritic index 
for each group was between 3 ,1-3.2 and all mice in each group demonstrated a positive arthritic 
index. Due to the variation in when each group reached an average arthritic index o f 3 .1 - 3.2, 
treatment initiation day varied from study day 29 (eight days after the second collagen injection) 
to study day 33 (12 days after the second collagen injection). The treatments lasted for 14 days 
in all groups before joints were harvested for histology. Limbs were preserved in 10% neutral 
buffered formalin for histology. Limbs were decalcified in formic acid for 2-3 days, paraffin 
embedded, and 8 uni sections stained with toluidine blue. Arthritis severity was evaluated for 
inflammation, pannus, cartilage damage, and bone damage.
CYTOKINE EVALUATION: Treatment was initiated when the average arthritic index for each 
group was 3.4 and all mice in each group demonstrated a positive arthritic index. All groups 
reached an average arthritic index of 3.4 on day 34 (13 days after the second collagen injection), 
and treatment was initiated. The treatments lasted for 1 day, at which time plasma and ankle 
joints were collected for cytokine analysis (described in detail in subsequent methods).
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All selection and later scoring were blinded to treatment. Data are represented as mean ± SEM. 
CIA - Cytokine or chemokine array
CIA was induced as described. 24 hours after treatment o f SecinHS, joints of mice were 
collected and pulverized using a mortar and pestle filled with liquid nitrogen. Tissue was 
transferred to 15 ml tubes, resuspended in 1 ml PBS and homogenized using a Polytron tissue 
homogenizer (PRO  Scientific Inc. USA) for 20 s. Mouse joint homogenates were centrifuged for 
10 minutes at 500 g at 4°C. Supematants were transferred to 1.5 ml Eppendorf tubes, centrifuged 
at 15,000 g for 5 minutes and collected for cytokine analysis by Quansys Biosciences. Data are 
presented as mean ± SEM for 6 mice per condition.
CIA -  Evans Blue permeability
CIA was induced as described. Seven days after randomization and treatment initiation, mice 
were given an IV injection o f 5 ml kg of 1% Evans Blue dye. One hour later, mice were bled 
and plasma collected. Mice were perfused, the hind limbs degloved, and ankle joints 
homogenized in 0.5 ml saline. 1.5 ml formamide was added and Evans Blue dye eluted 
overnight at 60°C. Supernatant and plasma samples were read spectrophotometrically and 
expressed as 0 0 6 2 0 -0 0 7 4 0  joints divided by O D 620-00740 plasma. Values were normalized 
to non-C'IA-induced mice and expressed as fold increase over control. N=14 per group and data 
are represented as mean ± SEM.
Air-Pouch Model
The Carrageenan-induced Air Pouch Model was performed by Washington Biotechnology as 
previously described39'41. All protocols were approved by their IACUC (Institutional Animal
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Care and Use Committee) prior to initiation o f the study. Six to seven week old male Swiss- 
Webster mice were used (Harlan) with 6-8 animals per group. On day 0, the nape of the neck 
was shaved and six mL o f  sterile air was injected subcutaneously. On day 3, three mL o f sterile 
air was injected subcutaneously. On days 4 and 5. mice that were to be induced at a later time 
were injected with either 0.1 mg/kg SecinH3 IP BID, vehicle IP BID, or 10 mg/kg Enbrel® SQ 
QD. On day 6 an additional injection was administered one hour prior to carrageenan 
injection. One mL o f 3% carrageenan (FLUKA) previously prepared in de-ionized water with 
heat, or l m L  of saline for the sham group, was then injected into the air pouch. Four hours after 
carrageenan injection, the mice were anesthetized and 3mL of 10 U/mL heparinized saline was 
injected into the air pouch. The air pouch was gently massaged, the contents immediately 
removed, and the exudate volumes recorded. An aliquot o f the exudate was transferred to 
heparin-treated microtainer tubes for differential white blood cell counting. Samples with 
bloody exudates were discarded from white blood cell counting.
Statistical analysis
For the majority o f  data, one-way ANOVA (analysis o f variance) with Tukey’s post-hoc test was 
used to assess statistical significance. A Student’s t-test was used when the experiment was only 
composed of two groups. Two-way ANOVA with Bonferroni post-hoc test was used to assess 
statistical significance for data shown in Figure 4b. A / ’-value of less than 0.05 was considered 
statistically significant. Unless otherwise noted, P-values of less than 0.05 are denoted with a 
single symbol (ie. *); P-values less than 0.01 are denoted with two symbols (ie **); P-values less 
than 0.001 are denoted with three symbols (ie ***); P-values less than 0.0001 are denoted with 
four symbols (ie ****), etc.
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CHAPTER 3
ARF6 PROMOTES ATHEROSCLEROSIS THROUGH MEDIATION 
OF ENDOTHELIAL MECHANOTRANSDUCTION
Atherosclerosis is the leading cause of death in developed nations, including the United States1. 
Since the 1980s, research has shown that the rheological properties of the vascular system play an 
important role in the pathophysiology of atherosclerosis2. While a variety of mechanical forces (including 
hydrostatic pressure and cyclic-stretch) have been shown to affect Endothelial Cell (EC) structure and 
function, shear stress has the most drastic and well-characterized effect. Laminar blood flow resulting in 
high net shear stress (blood flowing with little turbulence in a constant direction) has been found to be 
atheroprotective, while low net shear stress or oscillatory shear stress (blood flowing with rapid changes in 
direction or turbulence) has been shown to promote atherosclerosis3. Mechanosensitive cellular 
components are specifically activated by large rapid changes in shear stress both in vitro and in vivo 4. 
Disturbed flow has been shown to increase inflammation, cytokine release, and permeability of ECs in 
vitro, as well as inflammation and permeability in vivo. The activation or quiescence of the endothelium is 
thus determined by local shear stress patterns, as shown in Figure 3.1.
ECs sense and respond to shear stress through a variety of effectors, including ion channels 5, 
integrins 6, membrane-bound G proteins 7, the apical glycocalyx 8, primary cilia 9, and the VEGFR2/VE- 
Cadherin/PECAM-1 mechanosensory complex 10,11. While a variety of EC mechanotransduction 
mechanisms have been proposed, and several molecules have been shown to respond directly to shear 
stress, a comprehensive understanding of the interaction of each pathway has not been elucidated. 
Generally, it is proposed that fluid shear stress induces deformation of the apical surface of ECs and/or 
their glycocalyx, and that this deformation results in either direct activation of apical cell components or the
48
Figure 3.1. Rapid changes in fluid shear stress, as shown for oscillatory flow (a) and the onset of laminar 
flow (b) cause activation of endothelial cells. Endothelial cells exposed in vitro to low net-shear stress or 
rapidly reversing shear stresses do not align to the direction of flow (c) and express a sustained and marked 
increase in inflammatory and thrombotic markers. In contrast, the onset of steady or pulsatile laminar flow 
(b) induces transient endothelial activation, but as the cells adapt and align parallel to the direction of flow 
(d), the expression of inflammatory and thrombotic molecules decreases. In vivo (e), arterial regions 
distinguished by regular laminar flow are associated with a quiescent endothelial cell phenotype and low 
vessel-wall permeability. On the other hand, regions of disturbed flow show increased inflammation and 
monolayer permeability which are consistent with a pro-atherosclerotic phenotype and may play a role in 
the earliest stages of plaque formation.
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transduction of force throughout the cell via the cytoskeleton, resulting in the activation of additional 
components, including integrins on the basal surface. There is widespread agreement that shear stress leads 
to the downstream activation of a variety of pathways, including Rac, Rho, and MAPK, and further 
downstream ERK, JNK, NF-kB activation, and actin remodeling 12 All shear stresses are not equal, 
however; laminar flow, for example, induces ERK5 and subsequently, kruppel-like factor 2 (KLF2), which 
is known to establish quiescence in the endothelium13, while in regions of disturbed flow, constant 
activation of the MAPK pathways leads to expression of monocyte chemotactic protein-1 (MCP-1) as well 
as leukocyte adhesion molecules such as intercellular adhesion molecule 1 (ICAM1) 14,15.
ECs of virtually any type will align parallel to constant or pulsatile flow (both whole-cell 
alignment and alignment of actin fibers) after 16-24 hours of arterial shear stress (10-20 dynes/cm2). Cells 
cultured under static conditions, however, will show random orientation of actin fibers and no trend in 
whole-cell alignment. The alignment of cells to fluid shear stress is believed to be an adaptive mechanism 
to minimize the mechanical forces on the cells6. A lack of EC alignment when exposed to constant or 
pulsatile arterial shear stress indicates a possible modulation of EC mechanotransduction. EC alignment 
(both actin and whole-cell) parallel to flow is therefore a functional outcome and measure of an intact EC 
mechanotransduction system.
Despite data characterizing the critical role of disturbed flow on atherosclerosis, little work has 
been described that seeks to modulate these effects. The presence of regions of disturbed flow cannot be 
changed, as remodeling or replacement of the entire vascular system is impractical, and the requirement for 
blood throughout the body necessitates twists, turns, and bifurcations which induce disturbed flow. 
Therefore, one strategy could be to induce vascular stability by manipulating the ability of ECs to sense and 
respond to disturbed flow. This has proven to be a viable option, as demonstrated by the lab of Martin 
Schwartz, which identified PECAM-1 as a component of a mechanosensory complex which promoted 
vascular destabilization by disturbed flow6. By knocking out PECAM-1, the group showed that they had 
blunted EC mechanotransduction, and subsequently showed a significant decrease in atherosclerotic plaque 
formation in a PECAM-1--; Apo-E-- mouse compared to PECAM-1++; Apo-E-- mice 16 Additionally, they 
showed that this strategy markedly decreased NF-kB activation both in vitro and in vivo. This important 
work highlights the potential for manipulation of EC mechanotransduction as a strategy for combating
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atherosclerosis. Despite the promise of this work, PECAM-1 plays a critical role in a variety of physiologic 
processes, and inhibition could lead to increased susceptibility to certain permeability-related insults17. An 
ideal target in this pathway, therefore, would be a ligand-receptor-mediated pathway that blunts the 
deleterious effects of EC mechanotransduction while simultaneously supporting general vascular stability.
Slit2 is a repulsive neural guidance cue that has been implicated in a variety of processes in the 
vascular system, and specifically has been shown to effect vascular stability. While there is increasing data 
on the role of Slit2, its receptor and mechanism remain highly controversial. Our lab has proposed that 
Slit2 acts through the Robo4 receptor, a vascular-specific Roundabout receptor, and acts to inhibit Arf6 
activity18-20. The proposed Slit2/Robo4 pathway includes recruitment of paxillin to Robo4 and inhibition of 
the downstream pathways of VEGFR2 and integrin activation. Paxillin plays an important role in focal 
adhesion formation, a process required for EC alignment to flow21. VEGFR2 downstream signals are also 
required for EC responses to fluid shear stress11. The core of the Slit2/Robo4 pathway is ARF6, a small 
GTPase shown to play a prominent role in cytokine-induced inflammation in the previous chapter.
The possibility that both cytokine-induced inflammation and shear stress-induced inflammation 
and endothelial activation converge through a single node, ARF6, is exciting. Current athersclerosis 
therapy includes lifestyle modification, cholesterol lowering drugs (such as statins), hypertension 
medication, antiplatelet and anticoagulant medication (such as aspirin or clopidogrel), and medical 
treatment of conditions which increase atherosclerotic risk such as diabetes. All of these strategies act 
indirectly on atherosclerosis. This study seeks to address a risk factor for atherosclerosis which underlies 
the pathophysiology of plaque formation due to both oscillatory shear stress and inflamation, and is 
universal to all humans regardless of race or health.
Results
Using a parallel plate flow-chamber system 22, I have been able to induce alignment of actin 
filaments and whole-cells to flow in multiple human cell types, including Human Umbilical Vein 
Endothelial Cells (HUVEC), Human Dermal Micro-Vascular Endothelial Cells (HMVEC-D), and Human 
Coronary Artery Endothelial Cells (HCAECs). Cells were grown on fibronectin-coated slides and exposed 
to constant fluid shear stress of 12 dynes/cm2 (a physiologically relevant arterial shear stress) for 16-24
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Figure 3.2. Effects of various treatments on flow-induced endothelial alignment.
hours. I also have shown random alignment of actin filaments and whole cells similarly prepared but 
exposed only to static conditions. Whole cell alignment was measured manually, and actin alignment was 
measured both manually and using a custom software program I developed (detailed in Chapter 1, Figure
1.5).
I wondered what effect modulation of various components of the SLIT/ROBO/ARF pathway 
would have on the ability of endothelial cells to respond to shear stress by aligning in the direction of flow. 
To address this question, I first measured the alignment of endothelial cells to flow after treatment with 
Slit2N. I found that Slit2N decreases both whole cell and actin alignment to constant shear stress in 
HUVECS (Figure 3.2). Slit2N causes the effect across a dose-response of concentrations and in the context 
of a range of fibronectin concentrations, indicating that this response is not due to differences in exposed 
fibronectin concentrations. Further, a knockdown of Robo4 using siRNA partially inhibited the effect of 
Slit2N on decreasing endothelial alignment, suggesting that Robo4 is necessary for this interaction.
Next, I wondered whether inhibition of ARF6 using RNAi or small molecules would have an 
effect on endothelial alignment to flow. I found that knockdown of ARF6 or chemical inhibition of ARF6 
using SecinH3 reduced the ability of the cells to align to flow. A similar effect was seen for the reduction 
of the ARF-GEF ARNO via RNAi treatment. Further, inhibition of the ARF-GAP GIT1 using RNAi 
resulted in enhanced alignment to flow. Taken together, these data suggest that activation of the 
SLIT/ROBO pathway, leading to inhibition of ARF6, plays a role in limiting the mechanosensation of 
endothelial cells to fluid shear stress or limits the ability of the cells to respond to mechanosensory cues.
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To test whether inhibition of ARF6 plays a physiologically relevant role in atherosclerotic plaque 
formation, we used a partial carotid ligation model in mice with either both ARF6 alleles or with both 
ARF6 alleles knocked out in the endothelium. The partial carotid ligation procedure induces highly 
oscillatory flow in the left carotid artery while maintaining normal flow in the right carotid artery for 
comparison. All branches of the left carotid (with the exception of the superior thyroid artery) are ligated 
and the intended flow modulation is confirmed by ultrasound. To encourage lesion formation, mice were 
fed a high fat for 5 weeks prior to surgery and for 3 weeks after surgery. These mice were subsequently 
sacrificed, and plaque formation was quantified in both genotypes. We found that loss of endothelial ARF6 
reduced plaque formation and neointimal hyperplasia in response to left carotid ligation and subsequent 
oscillatory flow (Figure 3.3).
Conclusions
These data strongly suggest that ARF6 plays a role in promoting endothelial activation in response 
to dynamic shear stress. Whether this effect is through inhibition of mechanotransduction or through 
inhibition of other inflammatory pathways remains an open question. Additional work is needed to fully 
validate these results, and studies are ongoing.
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Figure 3.3. Representative left carotid artery from (a) wildtype and (b) endothelial-specific Arf6 knockout 
mice. (c) Method for quantifying neointima area. Comparison of neointima formation by (d) area and by 
(e) percentage. (f) Method for quantifying neointima thickness. Comparison of neointima thickness by (g) 
area and (h) ratio to healthy control vessel (right carotid)
CHAPTER 4
MUTATIONS IN 2 DISTINCT GENETIC PATHWAYS RESULT IN 
CEREBRAL CAVERNOUS MALFORMATIONS 
IN MICE
The following chapter was reprinted with permission from The Journal of Clinical Investigation. I 
was an author of this paper along with Aubrey C. Chan, Stavros G. Drakos, Oscar E. Ruiz, Alexander C.H. 
Smith, Jing Ling, Samuel F. Passi, Amber N. Stratman, Anastasia Sacharidou, M. Patricia Revelo, Allie H. 
Grossmann, Nikolaos A. Diakos, George E. Davis, Mark M. Metzstein, Kevin J. Whitehead, and Dean Y. 
Li. This article was originally published in The Journal of Clinical Investigation, 2011 May;121(5):1871- 
1881. This manuscript details the development of mouse models of cerebral cavernous malformation and 
the identification of these genes as critical in endothelial stability.
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Mutations in 2 distinct genetic pathways result 
in cerebral cavernous malformations in mice
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Cerebral cavernous m alform ations (CCMs) are a com m on type o f  vascular m alform ation in  the brain that 
are a major cause o f  hem orrhagic stroke. This condition  has been independently linked to 3 separate genes: 
Krevl interaction trapped (KRIT1), Cerebral cavernous m alform ation 2 {CCM2), and Programmed cell death  
10 (PDCD10). Despite the com m onality in  disease pathology caused by m utations in  these 3 genes, we found  
that the loss o f  PdcdlO results in  significantly different developm ental, cell biological, and signaling pheno­
types from  those seen in  the absence o f  Ccm2 and K ritl. PDCD10 bound to germ inal center kinase III (GCKIII) 
fam ily m embers, a subset o f  serine-threonine kinases, and facilitated lum en form ation by endothelial cells 
both in  vivo and in  vitro. These findings suggest that CCM may be a com m on tissue m anifestation o f  distinct 
m echanistic pathways. Nevertheless, loss o f  heterozygosity (LOH) for either PdcdlO or Ccm2 resulted in  CCMs 
in  mice. The m urine phenotype induced by loss o f  either protein reproduced all o f  the key clinical features 
observed in  hum an patients w ith CCM, as determined by direct com parison with genotype-specific hum an sur­
gical specim ens. These results suggest that CCM m aybe m ore effectively treated by directing therapies based 
on  the underlying genetic m utation rather than treating the condition as a single clinical entity.
In trodu c tion
Cerebral cavernous malformations (CCMs) are common vascular 
malformations with a prevalence of 1 in 200 to 250 individuals in 
unselected populations (1, 2). CCMs can lead to focal neurologi­
cal deficits, seizures, and hemorrhagic stroke, but no pharma­
cologic therapy currently exists (3). CCMs predominantly occur 
in the central nervous system and are characterized by subclini- 
cal bleeding and consequential hemosiderin deposits that are 
detected by MRI (4). MRI is the primary clinical modality for 
detection, diagnosis, and management o f CCMs. Hemosiderin 
deposits give CCMs an MRI appearance of a central mass with 
a dark perilesional halo, whose appearance is nearly diagnostic 
(pathognomonic) o f cavernous malformation (5). Cavernous 
malformations are characterized by a complex of vascular chan­
nels of varying sizes lined by a single layer o f endothelial cells 
without any abnormally large arteries, arterialized veins, or large 
venous outflow vessels. Although dense fibrillary neuroglial 
tissue may penetrate the mass, vascular channels are generally 
arranged in a back-to-back pattern with little or no intervening 
brain parenchyma. There is often a peripheral margin of gliotic 
tissue containing hemosiderin-laden macrophages (6).
CCMs can occur sporadically or be inherited in an autosomal 
dominant pattern. Familial CCM has been linked co heterozygos­
ity for any of 3 genes: Krevl interaction trapped (KRJT1), Cerebral 
cavernous malformation 2 (CCM2), and Programmed cell death 
10 (PDCD10) (7). All 3 proteins bind each other in coimmuno- 
precipitation experiments on cells overexpressing these proteins,
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leading to the hypothesis that they function as a complex to affect 
a common signaling mechanism (8). Both Kritl and Ccm2 are 
required for proper connection of the developing heart with the 
aorta to establish circulation in the mouse embryo (9, 10). Mice 
lacking either Kritl or Ccm2 fail to form a lumenized first bran­
chial arch artery to link the heart and aorta; as a result, mice lack­
ing either gene die at the same age. The requirement for Ccm2 is 
endothelial autonomous (9 ,11). In the endothelium, both KRIT1 
and CCM2 suppress the activity o f the small GTPase RhoA (9, 
12). Loss of either gene leads to RhoA activation and signaling 
through Rho kinase (ROCK) resulting in increased actin stress 
fibers, impaired cell-cell interactions, and increased vascular per­
meability (9 ,12 ,13). These defects can be reversed in cell culture 
and in mice with inhibitors of RhoA including HMG-CoA reduc­
tase inhibitors (statins) (9, 12).
A recent report suggested a similar mechanism of Rho activation 
for PDCD10 (14). However, other studies have suggested a different 
cell-signaling role for PDCD10. While KRIT1, CCM2, and PDCD10 
all occupy the cytoplasmic compartment of the cell, unique sub- 
cellular localization for each has been described, including nuclear 
localization ofKRITl (15) and Golgi localization ofPDCDIO (16). 
Each protein has also been found to have unique binding partners 
(17-19), PDCDlO’s binding partners include members of the germi­
nal center kinase III (GCKIII) subfamily of serine-threonine kinas­
es with homology to yeast sterile-20 (STE20) kinase (16, 20-23). 
Furthermore, the clinical features of CCM in KR1T1> CCM2, and 
PDCD 10 families have important differences (24,25), with PDCD10 
resulting in the most severe disease (24,26). It is possible that CCM 
disease is the common result of multiple unique mechanisms and 
may require unique therapeutic strategies to target the underlying 
disturbed cellular and signaling pathways.
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Table 1
Early growth arrest and death in em bryos lacking PdcdlO
Cross PdcdlO* x PdcdlO *
Genotype PdcdlO * PdcdlO * P d c d lO - Total litters
No. of progeny
E7.5 75 114 52 27
E8.0 9 13 0* 4
E8.5 27 45 0* 13
E9.0 1 5 0 1
>E9.0 7 8 0 3
The numbers of normal-appearing and viable offspring by genotype in 
matings between Pdcd10+'~ parents are shown. AAges at which growth- 
arrested embryos could be obtained.
Though the signaling and cellular mechanisms associated with 
the 3 known CCM proteins may be different, a common genetic 
mechanism of loss of heterozygosity (LOH) has been suggested 
for familial CCM disease (27-29). Familial CCM is more aggressive 
than sporadic disease, with an earlier age o f onset, increased risk 
o f hemorrhage and seizure, and an increased number of lesions (3, 
30-32). These observations have led to the hypothesis that CCM 
disease occurs by the Knudson 2-hit mechanism, similar to retino­
blastoma (33). There is limited evidence from human pathologic 
specimens to support an association o f LOH with CCM lesions. 
In a series of challenging experiments, a number o f investigators 
have identified biallelic mutations, 1 somatic and 1 germline, in 
the endothelium of a subset of patient samples (27,28,34). While 
LOH could not be confirmed for a number of samples, a total of 
4 cases have been described for KRIT1 and 1 case each for CCM2 
and PDCD10. Mice heterozygous for Kritl or Ccm2 do not develop 
cavernous malformations, and no examples of secondary somatic 
mutations have been reported (35,36).
To determine whether endothelial LOH is not simply associ­
ated with, but is causative for, CCM pathology, requires an animal 
model with a controlled genetic mutation that can be directed and 
detected in a tissue-specific manner. In this work, we use drug- 
inducible, tissue-specific strains o f Cre recombinase to target 
conditional null alleles of the CCM genes to test directly the 2-hit 
hypothesis for cavernous malformations. We demonstrate that 
PdcdlO differs substantially from Ccm2 in development, cell biol­
ogy, and signaling, yet LOH is the common genetic mechanism 
to cause CCMs in both genotypes. These findings suggest that 
PDCD10 influences different endothelial signaling pathways from 
KRIT1/CCM2 to lead to a common histopathology and imply that 
medical treatment to stabilize familial CCM may need to be devel­
oped and evaluated in a genotype-specific manner.
R esu lts
Loss o f PdcdlO results in embryonic lethal phenotypes distinct from loss o f 
Kritl or Ccm2. To determine the role of PdcdlO in development and 
disease, we developed a conditional null allele, PdcdlOflox, in which 
exons 4-8 are flanked with LoxP sites (Supplemental Figure 1; sup­
plemental material available online with this article; doi: 10.1172/ 
JCI44393DS1). This strategy also allowed us to generate a consti­
tutive null allele, PdcdlO~, by crossing mice carrying PdcdlOfl0* with 
a mouse strain expressing Cre recombinase in the germline (37). 
To characterize the role o f  PdcdlO in development, we intercrossed 
PdcdlOV- mice and harvested embryos at varying stages of devel­
opment. Surprisingly, we found that mice lacking PdcdlO died at 
a much earlier age than those deficient for either Kritl or Ccm2. 
Whereas Kritl and Ccm2 mice show growth arrest at E9.0 and die 
at E l 1 (9-11), the loss of PdcdlO leads to growth arrest at E8.0, after 
gastrulation, but prior to the onset o f circulation or the requirement 
for cardiovascular function (Table 1 and Supplemental Figure 1).
An earlier requirement for PdcdlO than Kritl or Ccm2 in devel­
opment does not preclude a shared role in the vascular system. 
Mice with endothelial loss o f Ccm2 phenocopy the constitutive 
null m utant (9 ,11), so we sought to determine whether mice with 
endothelial loss o f PdcdlO would also recapitulate the Ccm2 phe­
notype. Using the endothelial Tie2-Cre driver, the same Cre driver 
that we used to ablate Ccm2 (9), we found that although mice with 
endothelial loss of PdcdlO (Pdcdl (fi0X/~;Tie2-Cre) did not survive to 
birth, they had patent branchial arch arteries, a developed circula­
tory system, and were indistinguishable from control littermates at 
E9.5 (Supplemental Figure 2). Instead, we found that loss o f  PdcdlO 
in the endothelium leads to progressive enlargement of the cardi­
nal vein and other veins of the rostral embryo at El 1.5 (Figure 1). 
Venous enlargement was not due to abnormal cardiac structure or 
function (Figure 1 and Supplemental Figure 2), nor were defects 
observed in arteries o f the embryo (Figure 1 and Supplemental 
Figure 2). Death occurred due to hemorrhage from venous rup­
ture by E l3.5 (Table 2). Additionally, mice with loss of PdcdlO in 
neural and glial tissues induced by Nestin-Cre showed no vascular 
or any other obvious defects and were born alive (Supplemental 
Figure 2 and Supplemental Table 1). These observations suggest 
that PdcdlO is required in the endothelium for control o f  venous 
size and integrity, yet PdcdlO differs from Ccm2 in that it is not 
required for the establishment of circulation.
Loss ofPDCDl 0 does not affect RhoA signaling but results in lumen for­
mation defects. To explore the role of PDCD10 in endothelial cells, 
we depleted PDCD10 in human dermal microvascular endothelial 
cells (HMVEC) with siRNA (Supplemental Figure 3). Whereas the 
loss of CCM2 leads to an increase in actin stress fibers as a result 
of RhoA activation (9 ,12,13) and phosphorylation of myosin light 
chain-2 by Rho kinase (Figure 2), we observed none of these indica­
tors o f RhoA activation with the loss o f PDCD10 (Figure 2). Thus, 
the role o f PDCD10 in endothelial cell biology and signaling dif­
fers from that o f CCM2.
Having found that PDCDlO’s function in development differs 
from that o f CCM2, we sought to identify defects associated with 
PDCD10 depletion in assays relevant to vascular development. 
PDCDlO-depleted HUVECs showed defective function in a 3D 
angiogenesis assay. Endothelial cells plated in a collagen matrix 
spontaneously organize into complex multicellular capillary-like 
networks with lumens (38), but cells depleted of PDCD10 failed 
to organize themselves into a lumenized network (Supplemental 
Figure 4, A and B). We explored potential downstream signaling 
pathways using this assay. A growing body o f evidence suggests 
that PDCD10 interacts with the GCKIII subfamily of serine-threo- 
nine kinases (16, 21-23); we used siRNA to deplete cells of each of 
the subfamily members (Supplemental Figure 3). We observed no 
effect on lumen formation with the knockdown of STK25, STK24, 
orMST4 in HUVECs (Supplemental Figure 4C).
PdcdlO functionally associates with GCKIII in lumen formation. Because 
the GCKIII family members may be functionally redundant, we 
sought to validate the importance of the PDCD10-GCKIII interac­
tion in vivo and in a simpler genetic model. We chose the fruit fly, 
Drosophila melanogaster, in which the GCKIII family is represented by
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Human CCM2 Mouse Ccm2
find that mutations o f both PDCD10 and CCM2 result in a com­
mon pathologic expression of disease in both humans and mice. 
Surprisingly, this common disease endpoint does not constitute 
proof of a common disease mechanism. Whereas our previous work 
and the work of others found that Ccm2 and Kritl play similar roles 
in embryonic development, in vitro cell biology, and cell signaling 
(9,10,12,13), these roles differ from those we observe with PdcdlO. 
Unlike Kritl and Ccm2, PdcdlO is not required for development 
o f the branchial arch arteries that connect the heart to the aorta.
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Pathologic analysis of mouse and human CCM2-associated CCM. 
Paired analysis of histologic sections with human tissue on the left and 
mouse on the right. (A and B) H&E staining revealing back-to-back vas­
cular channels (arrows) and hemosiderin pigment (arrowhead) in sur­
rounding tissues. (C and D) Iron (blue) detected by Prussian blue stain 
highlights hemosiderin deposits in macrophages and surrounding brain 
tissue. (E and F) Fibrous matrix deposits (blue) identified by Masson’s 
trichrome staining with fibrous tissue surrounding vascular channels 
(arrows) and in surrounding gliotic brain. (G and H) Endothelial stain­
ing for CD34 (G) or CD31 (H) is positive in the cells lining the channels. 
(I and J) Elastin staining shows that vascular channels lack elastic 
laminae (arrows). The fibrous matrix surrounding channels includes 
laminin (K and L) and collagen IV (M and N). Scale bars: 200 um.
Rather, PdcdlO has an essential, nonendothelial role in develop­
ment not shared with Kritl or Ccm2 as well as an essential function 
in venous maturation. We further observe differences in cell biol­
ogy and signaling between PDCD10 and KRIT1 or CCM2; whereas 
the loss of KRIT1 or CCM2 leads to RhoA activation, increased Rho 
kinase activity, myosin light chain phosphorylation, and actin stress 
fiber formation (9, 12,13), we do not observe activation of this sig­
naling pathway in cells depleted of PDCD10. Instead, we found that 
PDCD10 signals primarily through the GCKIII family of kinases.
The similarity in human CCM disease caused by mutations in 
KRJT1, CCM2, and PDCD10 have led to an assumption that the 
proteins encoded by these genes function in a common signal­
ing pathway. This assumption has been supported by experi­
mental evidence showing binding between ectopically expressed, 
epitope-tagged proteins (7, 8). However, the complexities o f sig­
naling pathways and pathophysiology allow for multiple mecha­
nisms to converge on a common disease phenotype (Figure 8A). 
An example is hypertrophic cardiomyopathy, which was consid­
ered 1 disease until molecular genetics revealed that 2 different 
mechanisms (sarcomere function or metabolism), each affected 
by distinct genes, both result in pathologic hypertrophy (Figure 
8B and ref. 46). We propose that a similar scenario is involved in 
the pathogenesis o f CCM (Figure 8C).
There is controversy concerning the signaling pathways affect­
ed by PDCD10. Several reports suggest an essential role for bind­
ing GCKIII family serine-threonine kinases (16, 21-23). However, 
a recent characterization of mice carrying a different conditional 
allele o f PdcdlO showed that the loss o f  PdcdlO in endothelial 
cells substantially blocks VEGFR2 signaling and inhibits the ear­
liest stages o f developmental angiogenesis (47). The implication 
of VEGFR2 signaling through MAP kinases agrees with a previ­
ous report linking GCKIII kinases and ERK signaling (20). Our 
data contrast with these reports; we observe that the absence of 
PdcdlO in vivo leads to a localized vascular defect at a much later 
developmental stage, inconsistent with a panendothelial block 
of VEGF signaling. In cell culture, we have not found any inter­
action between PDCD10 and VEGF or ERK signaling (Supple­
mental Figure 11). We suspect that this disparity may be due to a 
difference in knockout strategy; however, our confidence in our 
allele is bolstered by our ability to induce CCM disease. Our data 
support the model that PDCD10 signals through the GCKIII 
family kinases, as we have observed in human endothelial cells 
and in Drosophila that PDCD10 binds to GCKIII family kinases 
and both are required for lumen formation. Previous reports have 
further suggested that GCKIII signals through RhoA to converge
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amplification (TSA) kit (PerkinElmer) according to the manufacturer’s 
instructions. To demonstrate tissue specificity o f PDFGb-iCreER72, brains 
from mice carrying a LacZ reporter allele were fixed and then stained 
with X-gal as previously described (48). Brains from mice carrying the 
Tomato-EGFP reporter allele were fixed and then embedded into OCT (Fish­
er Scientific) for fluorescent frozen sections. H&E staining o f embryos was 
performed using standard procedures.
For histology o f adult mouse brains, mouse skulls were fixed in 4% form­
aldehyde for a t least 3 days or zinc-buffered formalin overnight before the 
brain was removed and sliced into 4 coronal sections. These sections were 
embedded into paraffin by standard techniques. Prussian blue staining 
for iron and Masson’s trichrome staining o f mouse brain sections were 
performed using the Artisan system (DAKO) according to manufacturer’s 
instructions. Staining for elastin, laminin, and collagen IV was performed 
by the Immunohistochemistry Research and Development Lab a t ARUP 
Laboratories. Human CCM samples were stained in the same way as adult 
mouse brains except for CD34 staining, which was performed by the Cen­
tral Labs at Intermountain Medical Center (Murray, Utah, USA).
Fluorescent staining of mouse retinas. Mice were anesthetized using Avertin 
(2,2,2-tribromoethanol, 0.4 mg/g; Acros Organics) and perfused with fluo­
rescently conjugated tomato lectin (Vector Labs) as previously described 
(49) at a  dose o f 5 jxg/g body weight. After 5 minutes, mice were perfused 
with saline and then with 4% formaldehyde. Retinas were then extracted, 
stained, and mounted as previously described (50).
F igure 8
Convergence of different mechanistic pathways in common pathology. 
(A) Proposed schema for different genes acting on separate mecha­
nistic pathways, yet ultimately resulting in a common expression of 
disease. (B) Genetic studies of hypertrophic cardiomyopathy highlight 
genes that can be grouped broadly into 2 separate mechanistic path­
ways: sarcomeric proteins such as (3-myosin heavy chain (MYH7), 
and metabolic genes including adenosine monophosphate-activated 
protein kinase (PRKAG2). (C) Studies of mouse development, cell 
biology, and signaling suggest that KRIT1 and CCM2 signal through 
RhoA GTPase, while PDCD10 signals through GCKIII kinases to lead 
to cavernous malformations.
Analysis of mouse embryos. Confocal immunofluorescence o f embryos and 
fetal ultrasound were performed as previously described (9).
Transmission electron microscopy. Samples were fixed in 1% formaldehyde, 
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer with 8 mM CaCh 
and 2.4% sucrose, pH 7.4, for at least 3 days. Samples were then rinsed in 
0.1 M cacodylate buffer, postfixed in 2% osmium tetroxide in 0.1 M caco­
dylate buffer, rinsed in type I water, and then enbloc stained with satu­
rated aqueous uranyl acetate. Samples were dehydrated through a graded 
series o f ethanols, followed with final dehydration in acetone, and then 
infiltrated and embedded in an epoxy resin.
Thick sections and thin sections were cut on a  Leica EM UC6 ultramicro­
tome (Leica Microsystems). The thick secdons were cut with glass and the thin 
sections were cut with a diatome diamond knife. Thick sections were dried on 
glass slides and were stained with 1% toluidine blue O in 1% aqueous sodium 
borate. Thin sections were placed on 135 mesh copper hex grids and stained 
sequentially with saturated aqueous uranyl acetate and Reynolds lead citrare.
Sections were examined on an FEI Tecnai T-12 transmission electron 
microscope (FEI) at 80 KV. Images were taken on Kodak 4489 electron 
microscope film, developed with Kodak D-19 developer, fixed, washed, 
and dried. The negatives were scanned on an Epson Perfection Photo 4990 
flatbed scanner.
Cell culture. HUVEC and HMVEC were obtained from Lonza and grown 
according to the manufacturer’s instructions in EGM-2 media (HUVEC) or 
EGM-2MV media (HMVEC). Human embryonic kidney (HEK 293T) cells 
(ATCC) were grown in DMEM (Gibco; Invitrogen) with 10% fetal bovine 
serum (Bio-West) supplemented with antibiotics. EAHY cells were generously 
provided by Andrew Weyrich (University o f Utah) and were grown in DMEM 
with 10% fetal bovine serum and FIAT supplement (Sigma-Aldrich).
Transfection ofECs with siRNAs. Human CCM2 and PDCD10 siRNAs were 
obtained from Dharmacon. Luciferase GL2 duplex or nontargeting siRNA 
(Dharmacon) were used as controls. EC transfection with siRNAs was car­
ried out in growth media with 1% serum. Details o f the siRNA transfection 
protocol have been described previously (51).
RT-PCR. Total RNA was extracted from EC vasculogenesis assay a t indi­
cated time points or from siRNA-treated ECs using the ToTALLY RNA 
Isolation Kit (Ambion) according to the manufacturer’s instructions. RNA 
(1 ,ug) was reverse transcribed using AccuScript High Fidelity 1st strand 
cDNA synthesis k it (Stratagene; Agilent). RT-PCR amplification used 
the following primers: forward: 5'-AGACTTCACGGAGTCCCTTC-3', 
reverse: 5 -AGAAGGTCTGAAGTATTAAGTTGG-3'. For quantitative 
real-time PCR, total RNA was extracted from cultured endothelial cells 
or from embryos using the NucleoSpin RNA II Kit (Clontech) according 
to the manufacturer’s instructions. Reverse transcription was performed 
with random primers using the RETROScript Kit (Ambion). Quantitative 
PCR was performed with TaqMan assays (Applied Biosystems) for human 
CCM2, PDCD10, GAPDH, STK24, STK25, and MST4 or mouse PdcdlO and 
Gapdh. Quantification was performed by standard curve method, and
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CCM2 and PDCD10 Transcripts were normalized to GAPDH for compari­
sons. RT-PCR primers for embryonic PdcdlO transcripts were as follows: 
primer 4F: 5 -TTCACCGAGTCCCTCCTTCG-3'; primer 7/8R 5'-GAACA- 
CATTTATTGCCTTGCCATC-3'; primer IF: 5'-AAGTCCGTGCCTCAGTT- 
GCC-3'; and primer EGFP-R: 5'-TCCTCGCCCTTGCTCACC-3'.
Immunofluorcsccnt ccll staining. Glass chamber slides (Nalge Nunc; Thermo 
Fisher) were coated with hum an fibronectin (Biomedical Technologies 
Inc.), and transfected cells were seeded at 50,000 cells per well. Cells were 
fixed in 4% formaldehyde and actin cytoskeleton was visualized using flu­
orescently conjugated phalloidin (Molecular Probes; Invitrogen). Images 
were obtained with an Olympus FV300 confocal microscope.
Endothelial cell vasculogenesis in 3D collagen matrices. This assay was per­
formed as previously described (9, 38).
Immunoprecipitation and Western blotting. An expressed sequence tag (EST) 
for human PDCD10 (IMAGE: 3050540) was obtained from ATCC and cloned 
into a pcDNA3.1 Hygro+ plasmid (Invitrogen) modified to encode an N-ter- 
minal FLAG tag. ESTs for Drosophila PdcdlO and GCKU1 were obtained from 
the Drosophila Genomics Resource Center and cloned into a pcDNA3.1 
Hygro+ plasmid modified to encode an N-terminal FLAG tag (PdcdlO) or 
HA tag (GCKII1). PDCD10A18 constructs were made using nested PCR with 
primers designed to overlap and omit the 54 nucleotides encoding those 18 
amino acids. Plasmids were transfected into EAHY or HEK 293T cells using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruc­
tions, with a reduced dosage of DNA and lipofectamine for EAHY cells. Two 
days after transfection, cells were scraped into lysis buffer (50 mM Tris-HCl at 
pH 7.5,100 mM NaCl, 0.5% Triton X-100) supplemented with protease and 
phosphatase inhibitors and 1 mM DTT. A portion of cell lysate was retained 
as whole cell lysate and the rest precleared with normal mouse IgG conjugat­
ed to agarose beads (Santa Cruz Biotechnology Inc.) a t 4° C for 1 hour, then 
incubated with anti-FLAG resin at 4°C for 2 hours. The beads were washed 3 
times with lysis buffer, and bound proteins were eluted using Laemmli sam­
ple buffer. Presence o f FLAG-tagged PDCD10 proteins was detected using the 
anti-FLAG M2 antibody (Sigma-Aldrich). Presence of HA-tagged GCKIII was 
detected using an anti-HA antibody (Santa Cruz Biotechnology Inc.). Near- 
infrared secondary antibodies (LI-COR Biosciences) were used to probe the 
blots, which were visualized using the Odyssey system (LI-COR Biosciences).
Rabbit polyclonal antibody against PDCD 10 was from Proteintech Group. 
Rabbit antibodies against phospho-myosin light chain (Thrl8/Ser 19), phos- 
pho-VEGFR2 (Tyr 1175), total VEGFR2, phospho-PLCy (Tyr783), total PLCy, 
phospho-ERKl/2 (Thr202/Tyr204), and total ERK1/2 were from Cell Sig­
naling Technology. a-Actinin antibody (clone H-2) was from Santa Cruz Bio­
technology Inc. HRP-conjugated secondary antibodies were from Jackson 
ImmunoResearch. Western blots were developed using the ECL Plus Western 
blotting reagent (GE Healthcare) and Kodak Biomax MR film.
Drosophila strains. The GAL4/UAS system was used for tissue-specific 
RNAi knockdown (43). The driver used was btl-GAL4 (42), and RNAi tar­
geting constructs v 10945 3 (against Pdcdl0) (41),vl06841 (againstPdcdlO) 
(41), and v49559 (against GCKIII) (44) were obtained from the Vienna Dro­
sophila RNAi Center, For rescue experiments, full-length cDNAs for Dro­
sophila PdcdlO were cloned into a pUAST transformation vector containing 
an attb site for site-specific transformation (52) provided by Carl Thummel 
(University o f Utah). Transgenes were injected into docking sites VK00027 
(53) and attp0016 (52) by Genetic Services Inc., and homozygous lines were 
established by standard methods.
For cDNA rescue experiments, flies homozygous for the cDNA rescu­
ing construct on the third chromosome were crossed to a homozygous 
btl-GAL4UAS-GFP driver line on the second chromosome to generate 
transheterozygote flies (btl-GAL4, UAS-GFP/+; UAS-Rescue/+). Males o f this 
genotype were then crossed to virgin females homozygous for the RNAi 
targeting construct located on the second chromosome. GFP expression
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indicated the presence o f the btl-GAL4, UAS-GFP transgenes. All o f  these 
larvae contain 1 copy o f the RNAi targeting construct, and half also have 
the cDNA rescue transgene. Results shown used the v 109453 line, which 
targets the 3’ UTR o f PdcdlO. The vl06841 line showed similar results.
Analysis of tracheal tube formation in Drosophila larvae. Animals were scored 
at the prewandering third instar larval stage for tracheal defects. Animals 
were graded by scoring air filling in primary sprouts emanating from the 
dorsal trunk. All primary sprouts were scored bilaterally (at least 12 per 
larva). The animals were categorized as having severe, moderate, or mild 
defects or wild-type i f  they had 3 or more o f the following defects: (a) severe 
defects were truncations before the first bifurcation o f the primary side 
branches or immediately after branching; (b) moderate defects represent­
ed gaps in air filling with filled tubes on both sides; (c) mild defects were 
loss o f  air filling only in the fine terminal tubes. In the event that more 
than 1 criterion was met, the more severe category was selected. If  animals 
had fewer than 3 branches with a given defect, the less severe category was 
selected. Only animals with no defects were categorized as wild type.
Mouse and human experiments. All mouse experiments were approved by the 
University o f Utah Institutional Animal Care and Use Committee. Human 
tissue samples were obtained with written informed consent and provided 
by Connie Lee and Amy Akers (Angioma Alliance, Norfolk, Virginia, USA) 
and Randyjensen (University o f Utah). Human experiments were approved 
by the Institutional Review Board o f the University o f Utah.
Statistics. For actin stress fiber content, and for in vitro lumen formation 
with GCKIII kinases, we performed ANOVA with Tukey’s post hoc analy­
sis with an a  value o f 0.05. For in vitro lumen formation time course for 
PDCD10, we performed statistical comparisons between treatment groups 
with a 2-tailed paired-sample t test with an a  value o f  0.05. For the tracheal 
tube formation rescue experiment, we performed a x 2 test for independence 
with an a  value o f 0.05 (degrees o f freedom = 9). For CCM penetrance and 
lesion content, we performed a 2-tailed t  test with an a  value o f 0.05.
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E9.5 Pdcd10"°*/- Pdcd1(f°*/'; Tie2-Cre E12.5 Pdcd1(fcxU; Tie2-Cre PdcdlO1'0*'; Tie2-Cre
E12.5 PdcdlC?°*/- Pdcdl<?°*/; Nestin-Cre
Supplemental Figure 2. Endothelial knockout of PdcdlO does not affect establishment of 
circulation or cardiac structure. Neural knockout of PdcdlO is viable. (A-B) Whole-mount
fluorescent staining for CD31 in E9.5 P d cd l(fml~ (A) and P d cd l(fm/~; Tie2-Cre (B) embryos. 
Arrows denote the dorsal aorta. (C-D) Hematoxylin and CD31 staining in E12.5 P d cd l(fm/+; 
Tie2-Cre (C) and P d cd l(fm/~; Tie2-Cre (D) embryos. (E-F) Hematoxylin and a-smooth muscle 
actin staining in E12.5 P dcdl( f ox/+; Tie2-Cre (E) and P d cd l(fm/~; Tie2-Cre (F) embryos, a, 
atrium; v, ventricle; BAA, branchial arch artery; m, myocardium; PV, pulmonary valve. (G-H) 
Hematoxylin and eosin staining in E12.5 P d cd l(fm/+; Nestin-Cre (G) and Pdcdl Nestin- 
Cre (H) embryos. Asterisks denote the cardinal veins. Arrows denote the dorsal aorta. Scale 




Supplemental Figure 5. Loss of PclcdlO or GCKIII results in failure of tracheal tube 
lumenization in Drosophila. (A) The tracheal network of a Drosophila larva. A UAS-GFP 
transgene was used to label tracheal cells (left panel). Brightfield images of the same larva show 
air filling in lumens (middle panel). A cartoon representing the lumenized tube network (cyan) 
appears in the rightmost panel. (B-D) Tracheal tube lumen formation in flies expressing control 
RNAi (B), RNAi directed against PdcdlO (C), or RNAi directed against GCKIII (D) under the 
control of the tracheal-specific btJ-GAL4 driver. Arrowhead (in cartoon panel of B) indicates the 
primary trunk of a tracheal tube (where lumen truncation would indicate a severe phenotype), 
and arrows indicate the fine terminal branches (where lumen truncation would indicate a mild 
phenotype). Loss of PdcdlO or GCKIII results in similar air-filling defects. GFP expressing 
tracheal cells that lack air-filled lumens are outlined in red on the cartoon panels of C-D. Scale 






A /  . j  ^ v ^
* • / h  
r  -  • j  
. - ‘ . — -  
El N , rs ’ * r '' -J
LU ’ 1 '
co . v , v
Supplemental Figure 6. PDGFb-iCreER '  activity is specific to the endothelium. (A) X-gal
staining (blue) of brain from a 6 month old PDGFb-iCreER72; Rosa26-LacZ mouse that was 
given tamoxifen at birth. (B) Close-up of the boxed area in panel (A). (C-D) X-gal (blue) and 
CD31 (brown) staining of brain from a 6 month old PDGFb-iCreER72; Rosa26-LacZ mouse that 
was given tamoxifen at birth. (E-G) CD31 (magenta) staining of brain from a 12 day old 
PDGFb-iCreER7' ; Rosa26-ACTB-tdTomato,-EGFP mouse that was given tamoxifen at birth.
Cre activation converts ubiquitous tomato expression (not shown) to EGFP expression (green). 
(H-J) Neuron-specific enolase (NSE, magenta) staining of brain from a 12 day o\A PDGFb- 
iCreER72; Rosa26-ACTB-tdTomato,-EGFP mouse that was given tamoxifen at birth. Cre 
activation converts ubiquitous tomato expression (not shown) to EGFP expression (green). Scale 
bars in (A-B) = 1 mm. Scale bars in (C-J) =100 urn.
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Mouse PdcdlO  Mouse Ccm2
Supplemental Figure 7. LOH of either Ccm2 or PdcdlO results in a range of vascular 
malformations. Both mouse models of CCM exhibit the same spectrum of pathology. Both the 
PdcdlO (A, C, E, and G) and Ccm2 (B. D, F, and H) induced endothelial knockout models 
develop vascular lesions that exhibit the previously described spectrum of CCM pathology. 
Examples shown here include lesions consistent with solitary telangiectasias (A-B), multichannel 
"pristine" caverns (C-D), complex multichannel lesions with organizing thromboses (arrows in 
E-F), and multiple small caverns associated with heavy hemosiderin staining (arrowheads in G- 
H). Scale bars = 200 |um.
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Supplemental Figure 8. Loss of PdcdlO protein from PdcdlO (but not Ccm2) vascular 
lesions. An antibody against PdcdlO does not stain endothelial cells of a CCM lesion from a 
PdcdlO induced knockout mouse (upper panel) but does stain the endothelial cells of a CCM 
from a Ccm2 induced knockout mouse (bottom panel). Arrows indicate endothelial cells. Scale 





CCM postive CCM negative Total
. Nestin-Cre 0  6  6
0
1  PDGFb-iCreER12 16  0  16
5  Total 16  6  2 2
Fisher's exact test -  p < 0.0001
Supplemental Figure 10. Neural-specific deletion of Cem2 does not result in CCMs. (A-F)
Histology of Ccm2^ox/~; Nestin-Cre mouse brain at 6 months (A-B), 7 months (C-D), and 8 
months (E-F). Staining is Prussian blue for hemosiderin with nuclear fast red counterstain. No 
lesions are found in these brains, and no hemosiderin is apparent. Scale bars = 1 mm. (G) Table 




Cross_____________________________ Pdcdl(f°x/f,°x X PdcdlO+'~; Nestm-Cre
Genotype Pdcdl (f°x/+ Pdcdl ( fm/ Pdcdltfox/+; Nestm-Cre
Pdcdlff™'; 
Nestin-Cre
# of progeny 
E12.5 2 7 9 8
PI 12 17 1 7
Supplemental Table 1. Table showing numbers of living offspring by genotype in matings 
between P d cd l(fox/:flm and Pdcdl 0 ,/ ; Nestm-Cre parents.
CHAPTER 5
A SCALABLE DRUG REPURPOSING PLATFORM FOR A 
MONOGENIC STROKE DISEASE
There are at least 7,000 diseases designated as rare in the United States23. Taken as a whole, at 
least 25 million Americans are affected by a rare disease24. Disease-causing mutations of a single gene 
account for as many as 5,000 rare diseases, the largest subset23. The often arduous quest for a proper 
diagnosis and treatment by highly specialized practitioners is costly to our healthcare system and for 
families faced with a rare disease. Further, the high cost of drug development combined with relatively 
small markets strongly reduced commercial interest in these diseases. The Orphan Drug Act of 1983 and 
its subsequent amendments created regulatory and economic incentives for drug development in the rare 
disease space, and there have been major successes both for pharmaceutical companies and for rare-disease 
patients . However, more than 95% of rare diseases still have no approved treatment , .
An area of excitement and challenge in the pharmaceutical industry is drug repurposing 
(sometimes referred to as drug rediscovery or drug repositioning), whereby existing drugs are used for 
additional or alternative indications from those for which they were originally designed or intended25. The 
classic example of drug repurposing is that of sildenafil, intended originally to treat angina, but attaining 
blockbuster status for the treatment of erectile dysfunction26. The vast majority of drug repurposing 
successes can be attributed to serendipity or to a reasoned approach based on a deep understanding of a 
specific disease mechanism25. While these reasoned approaches may work for well-studied diseases, a 
complete picture of the molecular mechanisms associated with most rare diseases are lacking. Therefore, 
development of a scalable platform for drug repurposing with the potential to repurpose drugs across many 
rare diseases in a near simultaneous fashion would have considerable implications.
Over the past decade, we have studied a monogenic disease, Cerebral Cavernous Malformation 
(CCM), in an attempt to learn more about the molecular mechanisms underlying vascular stability and with 
an emphasis on the development of translational research. CCM is a hereditary hemorrhagic stroke
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syndrome characterized by the formation of vascular malformations in the central nervous system. CCM 
lesions are leaky and unstable, with chronic and acute bleeding leading to inflammation and stroke, 
respectively27. The only treatment for CCM is neurosurgical resection28. CCM occurs in two forms: 
sporadic and familial, which together affect as many as 1 in 200 individuals in the United States 29,30. 
However, the familial forms together only account for 20% of cases and thus qualify as rare diseases. The 
familial form of the disease is associated with loss-of-function mutations in one of three genes, KR1T1, 
CCM2, and PDCD1031. We have previously reported on a target-based drug repurposing strategy for 
CCM, and we show here results that caused us to rethink our target-centric approach32. As a result, we 
developed an unbiased drug discovery platform for identification of an effective therapeutic for CCM.
Here we report on our drug discovery platform, and two drugs we identified as potential treatments for 
CCM. We demonstrate that both of these compounds successfully reduce CCM lesions in a faithful mouse 
model of human CCM disease, and further demonstrate that these compounds illuminate the 
pathophysiology of the disease. We suggest that this drug discovery platform may be scalable to rapid 
identification of new treatments for many monogenic diseases.
Results
We and others have identified dysregulation of the small GTPase RHOA in cells lacking KRIT1 
or OSM as a possible pathogenic mechanism of CCM disease based on reasoned probing of the molecular 
mechanisms associated with the disease and a reductionist methodology to target identification33-35. 
Because of that approach, we suggested that statins, which inhibit RHOA activation through antagonistic 
activity on HMG-CoA reductase, might be repurposed to treat CCM disease32. To test this hypothesis, we 
developed murine genetic models of CCM disease. These mice are compound heterozygous with a loss of 
function mutation in any one of the three CCM genes (Krit1 , Osm , and Pdcd10 ), and a second allele 
flanked by loxp that can be knocked-out in a postnatal, tissue-specific inducible manner in the endothelium 
(PDGFb-iCreERT2)39. Strikingly, these mice develop CCM lesions that reproduce all of the pathologic 
aspects of human CCM disease. Much to our surprise, four months of simvastatin treatment did not result
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Figure 5.1: Simvastatin treatm ent has no effect on lesion burden in a murine model of CCM. Mice 
were treated with a diet enhanced with simvastatin for 4 months. At 5 months of age, the lesion number in 
this group was compared with mice fed a standard control diet using small animal MRI analysis.
in a decreased burden of disease in these mice (Figure 5.1). While potential explanations for this result are 
myriad and do not exclude a role of RHO activation in CCM pathophysiology, or even of the use of statins 
as an effective treatment of CCM disease, this result forced us to critically reexamine our preconceived 
notions about the reductionist target-centric approach to drug discovery we had employed.
We have previously reported that endothelial cells deficient in CCM2 have obvious structural and 
functional phenotypes38. We hypothesized that we could use these phenotypes for unbiased drug discovery. 
Our strategy was to develop a primary imaging screen based on rescue of the structural defects associated 
with the loss of CCM2 and an orthogonal secondary screen based upon rescue of functional defects 
associated with the loss of CCM2 (Figure 5.2). Another important aspect of our strategy was to use a 
library of 1600 small molecules composed of known drugs and bioactive compounds based upon our 
hypothesis that hits from this library could more quickly be translated to the bedside.
To develop our high-content imaging primary screen, we first defined a set of imaging constraints. 
Images would need to (i) support computational recognition of cell nuclei and cell borders, (ii) be captured 
at a resolution sufficient to allow quantification of structural phenotypes, (iii) be amenable to a 96 or 384- 
well plate format, and (iv) be highly reproducible. To satisfy these demands, Human Dermal 
Microvascular Endothelial Cells (HMVEC-D) were treated with CCM2 mRNA-targeting siRNA or a 
scrambled control, and then seeded into 96-well imaging plates. Large immunofluorescence images were
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Figure 5.2: Workflow of chemical suppressor screen. The primary screen consists of a high-content 
immunofluorescence-based assay. The secondary screen consists of a nonoptical electrical cell substrate 
impedance sensing assay. Compounds in the primary screen were analyzed by qualitative human analysis 
or by automated machine-learning software; compounds identified by the software analysis had a much 
improved hit-rate in the secondary screen. Our structure-function screening system is amenable to a wide- 
variety of cell-types and disease states.
captured from each well of a 96-well plate in three channels sufficient to give an impression of the cell 
structure, including the nucleus, actin stress fibers, and VE-cadherin cell-cell junctions (Figure 5.3a-c and 
Figure 5.4). A high-throughput microscope developed for phenotypic drug discovery allowed automated 
imaging of an entire 96-well plate in about 60 minutes. We wrote a custom pipeline in CellProfiler, an 
open-source image analysis tool from the Broad Institute, to import images, define the borders of each cell, 
and create a database of a multitude of mathematical descriptors of the structure of each cell (Figure 5.3d 
and Figure 5.4)40. We then used CellProfiler Analyst, a machine-learning tool, to identify rules that could 
be used to distinguish whether each cell in an image was more likely to have been treated with scrambled 
control siRNA or siCCM241,42. The software was able to accurately categorize images as ‘siCTRL-treated’ 
or ‘siCCM2-treated’, resulting in a Z ’ of 0.7, which is considered amenable to high-throughput screening 
(Figure 5.3e and Figure 5.5) 43.
We then screened 1,600 known drugs to identify those that could rescue the structural phenotype 
associated with loss of CCM2. We analyzed the resulting images to identify rescue using CellProfiler and 
CellProfiler Analyst and qualitative analysis by two blinded reviewers as a comparison. Reviewers 
performing qualitative analysis commonly identified 38 compounds that when added to siCCM2-treated 
cells resulted in rescue of structural phenotypes (Figure 5.2). We simultaneously ran the images through
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Figure 5.3: Structural and functional phenotypes associated with loss of CCM2. (a) CCM2 was 
knocked down at least 80% in all assays as determined by western blot. (b) Endothelial cells treated with 
scrambled siRNA show a typical cobblestone monolayer phenotype with cortical actin (green) and VE- 
cadherin (red) at cell-cell borders, and a paucity of actin stress fibers. (c) Endothelial cells treated with 
CCM2 siRNA show an obvious cytoskeletal phenotype with a large number of actin stress fibers, decreased 
cortical actin, and increased cell-size. (d) Quantification of various parameters from thousands of cells. (e) 
Validation of machine-learning software to correctly classify images. Example primary hit from (f) 
qualitative or (G) automated analysis of the high-content imaging screen. (h) siCTRL treated cells reach 
and maintain a higher level of ECIS resistance compared to siCCM2-treated cells. (i) Eight compounds 
significantly improve barrier function in endothelial cells deficient in CCM2 after 24-hours of treatment. 
Scale bars = 50 ^m. All graphs depict mean ± SD.
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Figure 5.4: Large image quality control. (a) raw 4x4 montage image obtained using the BD Pathway 
Bioimager without correction filters. (b) The same image after correction filters were applied using 
CellProfiler software to eliminate montage and light-path artifacts. The inset demonstrates the high- 
resolution of these large montage images. Scale bars represent 100 ^M or 50 ^M (inset).
the CellProfiler software system, and we selected the 38 compounds that quantitatively rescued the 
structural phenotype most (Figure 5.2). Interestingly, there was no overlap between the compounds 
selected by human analysis and those selected by our automated computational scoring system.
To validate our hits and prioritize future analysis, we developed a secondary orthogonal screen 
using trans-cellular resistance based on the functional defect in monolayer stability in cells deficient in 
CCM233. Trans-endothelial resistance works by taking real-time measurements of the resistance 
encountered when an electrical current is passed between electrodes upon which cells are growing44. Using 
this trans-endothelial resistance assay, we simultaneously screened the two sets of 38 compounds identified 
by our manual and automated image analysis approaches in our primary screen. Of the 38 compounds 
selected by human analysis, only one compound (simvastatin) showed any significant rescue of the defect 
in monolayer stability of cells treated with siCCM2. Excitingly, 7 of the 38 compounds identified using 
our automated machine-learning analysis showed full or partial rescue of the same phenotype (Figure 5.3g). 
The eight compounds identified in our secondary screen include compounds from classes previously 
connected to CCM disease, as well as novel compounds (Figure 5.6).
Due to the time and cost associated with chronic treatment trials in our CCM mouse model, we 
first took advantage of a microvascular leak phenotype in our mice to quickly prioritize our hits for chronic 
treatment models. We found that our endothelial specific Ccm2 knockout mouse (Ccm2f/"; Pdgfb-iCreER1'2’ 
+-) had increased dermal vascular leak as measured by a modified Miles assay compared to wild-type
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Figure 5.5: Software analysis of immunofluorescence images. (a) DAPI images are used to seed a 
database with primary elements called ‘nuclei’ which are then represented as unique by false coloration.
(b) VE-cadherin images are used to detect cell-cell borders delineating the border separating the cytoplasm 
surrounding each ‘nuclei’, thereby establishing the individual ‘cell’ elements in each image, also 
represented as unique by false coloration. Calculations are made for each ‘cell’ for a wide variety of 
mathematical descriptors, including (c) the radial distribution of VE-cadherin in each cell, and (d) the 
number of neighbors and percent of cell borders touching other cells.
controls (Ccm2f,+; Pdgfb-iCreERT2, " "). When we injected small intradermal wheals of a subset of our hit 
compounds into these mice, we found that only tempol and cholecalciferol significantly reduced peri- 
injection microvascular leakiness (Figure 5.7). We do not exclude the possibility that the other compounds 
could be relevant therapeutic candidates for the treatment of CCM disease, but we elected to prioritize 
tempol and cholecalciferol for further study.
Next, we performed chronic treatment studies of the effects of tempol and cholecalciferol in our
fV T1'?inducible endothelial-specific Ccm2 knockout mouse (Ccm2 "; Pdgfb-iCreER )  . These studies would 
serve not just to evaluate the potential of these treatments for CCM disease, but as a litmus test for the 





Figure 5.6: Hits from secondary screen. Drug candidates were identified using (a) qualitative human 
analysis or (b-h) automated machine learning algorithms that subsequently rescued a functional monolayer 
defect in the secondary screen. Scale bars represent 50 ^M.
cholecalciferol), an identical chow enhanced with cholecalciferol (25 IU/g), or standard chow plus tempol 
dissolved in drinking water (1mM) starting 5 days after delivery of their pups. Treatment with a 
cholecalciferol-enhanced diet resulted in significantly different levels of the serum marker of 
cholecalciferol, 25(OH)D3, in pups by weaning (Figure 5.8). After weaning, mice were fed the same diet as 
their mother until 5 months of age, a point at which 100% of endothelial specific Ccm2 knockout mice have 
cerebrovascular lesions detectable by MRI. At this time, mice were evaluated for lesion status. Two 
blinded reviewers independently evaluated the number and size of CCM lesions using MRI; mice receiving 
the diet enriched with D3 or tempol had approximately half as many lesions and half the lesion area 
compared to those receiving standard chow (Figure 5.9a,b). The effect of cholecalciferol and tempol
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Figure 5.7: In vivo validation of candidates in a mouse model of CCM. Quantification of dermal 
permeability 1.5 hours after an intradermal injection of DMSO, cholecalciferol, gedunin, pindolol, or 
tempol and 30 minutes after intravenous administration of Evans blue dye. At least 12 mice per group were 
tested. All graphs depict mean ± SEM. * denotes P<0.05
supplementation was qualitatively obvious when comparing MRI-based three-dimensional reconstructions 
of representative brains and lesions (Figure 5.9c-e).
A major advantage of screening with a library of known drugs and bioactive factors is that a large 
body of research is generally available regarding the effects of any one of the compounds. Therefore, each 
validated hit has the potential to immediately inform the pathophysiology under investigation. Further, 
reagents and probes are more readily available for further study for such compounds.
With knowledge of the various biologic roles of cholecalciferol and other forms of vitamin D at 
hand, we assessed the timing of the effects of cholecalciferol on the endothelium. We found that 
knockdown of CCM2 led to increased activation of various pathways relevant to endothelial stability, 
including transforming protein RhoA (RHOA), phosphorylation of myosin light chain (pMLC), and ADP- 
ribosylation factor 6 (ARF6) (Figure 5.10a-c). Subsequently, we determined that treatment of monolayers 
with cholecalciferol, even at a lower physiologic dose (100 nm), inhibited the CCM2 knockdown-induced 
activation of RHOA, pMLC, and ARF6. We further examined the effect of cholecalciferol on ARF6 
activation, finding inhibition to occur within 5 minutes in cells induced by loss of CCM2 (Figure 5.10d-e). 
Knockdown of CCM2 did not affect activation of other proteins known to be important in endothelial 
stability, including cell division control protein 42 homolog (CDC42), Ras-related C3 botulinum toxin
C C M  2 f/+
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Figure 5.8: A cholecalciferol-enhanced diet promotes increased 25(OH)D3 levels before weaning. At
5 days after birth, litters were randomized to receive either standard chow (1.5 IU/g D3) or cholecalciferol- 
enhanced chow (25 IU/g D3). Because pups have not been weaned at this time-point, the indicated food 
was provided to the mother. Levels of the cholecalciferol metabolite, 25(OH)D3, were measured at P21, 
the day of weaning, and indicate that 16 days of dietary modification via mother’s breast milk can 
significantly increase 25(OH)D3 levels in pups. All bars represent mean ± SEM. * indicates P<0.05.
substrate 1 (RAC1), or Ras-related protein R-Ras (RRAS); nor did treatment of up to 10 ^M 
cholecalciferol basally inhibit activation of these markers (Figure 5.11). Taken together, these data suggest 
that cholecalciferol, even at physiologic doses, can rapidly inhibit multiple key intracellular signaling 
pathways that play a role in endothelial activation in the context of mutation-induced destabilization.
These data shed light on CCM, and also inform the study of cholecalciferol, which has not previously been 
shown to have these specific effects on cell signaling.
The specific target of our second hit, tempol, is superoxide scavenging. Indeed, a role of oxidative 
stress in the pathophysiology of CCM disease due to two other causative genes, KRIT1 and PDCD10, has 
been reported45-47. In cell culture, loss of CCM2 induced increased ROS and decreased F0X01 expression, 
suggesting a potential common mechanism of CCM pathophysiology as has been proposed for KRIT1 
(Figure 5.10)45. These results, and previous work in the field, led us to hypothesize that oxidative stress 
may be a driving force in CCM at the level of individual cells and may also have broader effects on the 
physiology of small vessels through effects on endothelial vasodilation48. To test this hypothesis, we 
isolated murine middle cerebral arteries from our endothelial-specific CCM2 knockout mice, and measured 
both endothelial-dependent and endothelial-independent vasodilation49. We found that endothelial-specific 
loss of CCM2 resulted in a significant defect in endothelial-dependent vasodilation in our model, which
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Figure 5.9: Treatment with cholecalciferol or tempol reduces lesion severity in a CCM mouse model.
(a) Endothelial-specific Ccm2 knockout mice fed a diet high in cholecalciferol or tempol had fewer CCM- 
like lesions in the brain after 5 months as measured by MRI. Three-dimensional reconstructions from MRI 
data of the brains of mice with the median number of lesions from (b) the untreated group, (c) the 
cholecalciferol treated group, or (d) the tempol treated group demonstrate the qualitative reduction in 
lesions (red). Experiment represents at least N=8 mice per group. All graphs depict mean ± SEM. * 
denotes P<0.05
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Figure 5.10: Treatments illuminate pathophysiology of disease. 60-minute treatment with 100 nM 
cholecalciferol, but not its precursor 7-DHC, rescues CCM2 knockdown-induced (a) RHOA, (b) pMLC, 
and (c) ARF6 activation. (d) Cholecalciferol rescues CCM2-induced activation of ARF6 within 5 minutes. 
(e) Quantification of (d). (f) Knockdown of CCM2 in EAHY cells induces increased reactive oxygen 
species. (g) Knockdown of CCM2 in XYZ cells induces a reduction of F0X01 expression. All graphs 
depict mean ± SEM. * denotes P<0.05, ** denotes P<0.01, and *** denotes P<0.001
could be completely rescued by tempol (Figure 5.12a-d). Additionally, both systolic and diastolic blood 
pressure were increased in the endothelial knockout mice (Figure 5.12e-g), consistent with constricted, 
non-responsive vessels. Interestingly, heart rate of the endothelial knockouts was lower than in control 
mice (Figure 5.12h). Taken together, these data suggest that CCM2 could play an important role in 
regulating cellular functions directly related to the endothelium, and that dysregulation of these functions 
may cause perturbances to important organ-level hemodynamic systems. These results have potential 
implications for understanding the pathophysiology of CCM disease, and suggest that hemodynamics in 
patients with CCM should be monitored closely.
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Figure 5.11: Cholecalciferol has no effect on the activation of certain destabilizing pathways in the 
endothelium. 60-minute treatment with 10 cholecalciferol had no effect on activation of (a) RAC1, 
(b) CDC-42, or (c) R-RAS in endothelial cells. All bars represent mean ± SEM.
As a result of our repurposing strategy, we identified not only potential treatments of CCM 
disease, but also informed the study of the molecular mechanisms of the disease. Further, the compounds 
we identified are associated with specific biomarkers that may aid in the evaluation of CCM disease.
Methods
Reagents. Primary human adult dermal microvascular endothelial cells (HMVEC-D) and cell 
culture reagents were obtained from Lonza (Basel, Switzerland). Small interfering RNA (siRNA) were 
obtained from Dharmacon Thermo Scientific (Waltham, MA). The Spectrum Collection compound library 
was obtained from MicroSource Discovery Systems (Gaylordsville, CT), via the University of Utah Drug 
Screening Resource. 7-DHC was obtained from Sigma-Aldrich (St. Louis, MO). All remaining reagents 
were obtained from Tocris Biosciences (Bristol, U.K.) unless otherwise stated.
Cell culture. Four individual lots of Adult Dermal Human Microvascular Endothelial Cells 
(HMVEC-D) were pooled at passage 0 and expanded according to manufacturer’s instructions in EBM-2 
media (Lonza) supplemented with EGM-2 MV Bulletkits (Lonza). After two expansions, cells were frozen 
in identical lots at 1x106 cells/mL for use in all screening experiments. Individual lots of HMVEC-D were 
expanded as described above and utilized for all mechanism experiments. All in vitro experiments were 
completed using endothelial cells between passage 3 and 6. The continuous human endothelial cell line
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Figure 5.12: CCM mice display endothelial-dependent vascular dysfunction. (a) Middle cerebral 
arteries isolated from endothelial-specific CCM2 knockout mice (KO) subjected to acetylcholine-induced 
vasodilation. (b) Sodium Nitroprusside treatment (an NO-donor) of middle cerebral arteries of both mice 
genotypes demonstrates the normal function of the smooth muscle in both wild-type and knockout mice.
(c) L-name, a specific inhibitor of eNOS, eliminates the ability of endothelial cells to produce NO. (d) 
Tempol completely rescues acetylcholine-induced vasodilation in endothelial-specific CCM2 knockout 
mice. (e) Systolic, (f) diastolic, (g) and mean blood pressure were elevated in CCM2 knockout mice, 
consistent with decreased vasodilatory function. (h) Heart rate was increased in the CCM2 knockout mice. 
All panels depict mean ± SEM. * denotes P<0.05
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EA-hy926 was maintained according to the protocol provided by the distributor (ATCC cat. CRL 2922, 
Manassas, Virginia, USA). Specifically, cells were cultured in DMEM medium with 25 mM glucose (HG) 
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 2% HAT supplement.
Endothelial transfection. ON-TARGETplus siRNA targeting CCM2 (5’ 
GGAAUUGUCUCGCCAUUUA 3’) or a scrambled control was obtained from Dharmacon. Endothelial 
cell transfection with siRNA was carried out as previously described7. Briefly, cells were passaged into 
25nM siRNA with 1:166 HiPerFect reagent (Qiagen) in 4:1 EGM-2 MV to EBM-2, respectively, and 
plated. After an overnight incubation in the transfection mix, cells were washed and fed with EGM-2 MV. 
After an additional 48 hours, the transfection process was repeated to achieve more complete knockdown. 
During the second transfection, cells were seeded into assay plates as described elsewhere. Cells were 
again fed with EGM-2 MV after overnight incubation with the transfection mix. After an additional 48-72 
hours, cells were subjected to experimental conditions.
EA-hy926 transfection. EA-hy926 endothelial cells (1x106) were plated in 10 cm culture dishes 
in 8 ml antibiotic-free standard growth medium supplemented with FBS. Cells were grown to 60% 
confluence and then transfected for 5 h at 37°C with either CCM2, CCM3, or control siRNAs (final 
concentration: 100 nmol/L). Specifically, silencing experiments were performed using CCM2 and CCM3 
siRNAs from Dharmacon (Dharmacon ON Target Plus J-014728-05-0050 and J-004436-05-0050, 
respectively). Cell transfections were performed using INTERFERin kit (Polyplus transfection, New York, 
NY, USA) according to the manufacturer's protocol. Cells were cultured with siRNAs for 24 h before 
treatments and analysis.
Immunofluorescence imaging: 96-well imaging plates (BD Falcon) were used for 
immunofluorescent imaging screening. Cells were fixed with 4% paraformaldehyde in PBS for 10 
minutes, washed 3x in ultrasaline (Lonza), then incubated overnight with mouse anti-human CD144 
antibody (BD Biosciences). Cells were washed 3x with ultrasaline, then a mixture of Hoescht 33342, 
Alexa-Fluor 488 Phalloidin (Invitrogen), and Alexa-fluor 594 goat anti-mouse antibody in ultrasaline were 
added for 6 hours. After an additional 3 washes, 200 ^l ultrasaline was added to each well, and then the 
plates were covered with adhesive foil and immediately imaged. 96-well imaging plates were imaged 
using a high-throughput BD Pathway 855 Bioimager. A custom macro was written using the Attovision
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software (BD) encompassing imaging autofocus at each well, followed by acquisition of each channel. 
Each image consisted of a 4x4 montage using a 40x objective, covering a total area of 810 x 600 ^m in 
each well. Images were automatically saved, and each plate was changed by hand when imaging was 
complete.
Automated image analysis. Images were analyzed using CellProfiler and CellProfiler Analyst.
A custom CellProfiler pipeline imported all images, applied a light correction filter, and decreased the size 
of the images to reduce imaging time. The Hoescht channel was first utilized to identify nuclei using an 
Otsu Global thresholding method. The VE-cadherin channel was utilized next to identify cell-cell borders 
again using an Otsu Global thresholding method minimizing entropy. A threshold correction factor of 0.7 
and a regularization factor of 0.001 were used. Cells not completely enclosed within the image were 
excluded from analysis. A variety of quantifications were calculated and recorded for each cell, including 
co-localization of each channel, radial localization of actin and VE-cadherin, texture of actin and VE- 
cadherin, nuclear and cell shape characteristics, etc. These quantifications were stored in a database 
accessible by CellProfiler Analyst. CellProfiler Analyst was subsequently used to open 100 control images 
(siCTRL or siCCM2 treated). Approximately 100 cells were selected at random from each control image 
and added to categorization bins if qualitatively meeting their respective prototypic phenotype. This 
process was repeated until approximately 10,000 cells comprised each bin; positive (siCCM2) and negative 
(siCTRL). Subsequently, rules were automatically developed using machine-learning algorithms to sort 
these cell populations based on their quantitative descriptions (as previously calculated for each cell and 
stored in MySQL database). Previously unused control images (siCTRL or siCCM2 treated) were then 
evaluated using the rules, and obvious miscategorization of cells was corrected. Cells not meeting the 
prototypic phenotype for a given treatment were not evaluated. After rule refinement and minimization, 
images from wells treated with each screen compound were evaluated. Compounds changing the score of 
an siCCM2-treated well to within three standard deviations of the siCTRL-treated mean score in both N= 1 
and N=2 of the primary screen were considered hits (n=38).
Drug treatment. Compounds were obtained in 100% DMSO at 2 mM concentration in 96-well 
polypropylene assay plates from the University of Utah Drug Screening Resource Core and kept frozen at - 
20°C. Libraries acquired included the Microsource Spectrum Library of exactly 2000 known drugs and
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bioactive compounds. At the time of treatment, drugs were added to 96-well imaging plates containing 
confluent siCCM2 treated HMVEC-D endothelial monolayers using a 12-channel electronic pipette 
(Eppendorf Xplorer) at final concentration of 10uM, 0.5% DMSO (vehicle) in starvation media (EBM-2 + 
0.2% bovine serum albumin) and gently mixed. Positive (siCCM2) and negative (siCTRL) control wells 
received 0.5% DMSO in starvation media without any compound treatment. Follow-up experiments were 
performed using the highest available grade of reagent from Tocris or Sigma.
Electric cell substrate impedance sensing. For screening applications, a 96-well ECIS plate 
(96W10E+, Applied Biophysics) was used. At the second siRNA transfection, HMVEC-D were seeded at 
4x104 cell/well. Plates were monitored using an ECIS Z0 system (Applied Biophysics) to measure 
impedance of an alternating current across the cell monolayer. Resistance was normalized for each well to 
just before treatment, and was plotted in real time. Cells were fed according to the same schedule as in the 
transfection protocol. 72 hours after the second siRNA transfection, compounds were added to each well at 
a final concentration of 10 ^M in 0.5% DMSO.
Mouse strains. Mice used have been previously reported iL—. Briefly, a construct for the 
conditional Ccm2 allele was derive from genomic sequence data from a BAC clone (RP22 library, 
Invitrogen). The construct extended from a Sail site 5’ of exon 3 through a BamHI site 3 ’ of exon 10. All 
mice were backcrossed into the C57BL/6J strain. PDGFb-iCreERT2 mice were generously provided by 
Marcus Fruttiger (University College London Institute of Ophthalmology, London, United Kingdom) via 
Holger Gerhardt (London Research Institute -  Cancer Research UK, London, United Kingdom).
Genotypes were determined by PCR analysis of genomic DNA isolated from ear biopsies using previously 
described primers. Tamoxifen (Sigma-Aldrich) was resuspended in corn oil (Sigma-Aldrich), and 40 ng 
was given as an intraperitoneal injection to mouse pups on perinatal day 1. ‘Control’ and ‘Wild-type’ mice 
were CCM2f/+ and tamoxifen-treated (but without PDGF-cre).
Dermal permeability. We performed a modification of a previously described Miles Assay —. 
Male mice between 2 and 4 months of age were anesthetized with isoflurane and their backs gently shaved 
and depilated using a hair-removal cream. The mice were then gently washed and allowed to recover. The 
following day, the mice were again anesthetized with isoflurane and 20 ^L intradermal injections of 
treatments (50 uM in 0.5% DMSO in sterile saline) in various positions on the back. 90 minutes later, we
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performed tail vein injections of Evans blue dye (100 ^L of 1% dye in sterile saline, Sigma). After 30 
minutes, mice were sacrificed and equal-sized skin biopsies from each injection site were collected and 
placed in formamide (Invitrogen) overnight at 60°C. Absorbance at 620 nm (measurement of blue dye) and 
740 nm (to normalize for any blood in the sample) was used to quantify the amount of Evans blue dye in 
each sample. The absorbance is reported with the standard error of the mean.
M urine CCM lesion formation and M RI analysis. At 5 days after birth (P5), litters were 
assigned to either a standard chow (Harlan 2018, 1.5 IU/g D3) or D3 enhanced chow (Harlan 2018 + 25 
IU/g D3). The chow was provided to the mother of each litter until the mice were weaned at P21. Mice 
from each litter continued on their respective diets until 5 months of age. At 5 months of age, mice were 
sacrificed by exsanguination (blood was collected for later analysis), and subsequent perfusion with saline 
and then 4% formalin. Brains were dissected from the skull. Postmortem MRI scanning was subsequently 
performed. A gradient recalled echo sequence was used to acquire coronal slices spanning the whole 
brain. Sequence parameters were as follows: repetition time, 328 ms; echo time, 5.4 ms; flip-angle, 40°; 12 
averages, in-plane-resolution, 125 ^m x 125 ^m; and slice thickness, 0.5 mm. For a representative subset 
of brains, high-resolution 3D gradient echo was acquired using the following parameters: isotropic voxel 
size of 78 ^m x 78 ^m x 78 ^m over 9 hours. Other sequence parameters were as follows: repetition time, 
250 ms; echo time, 7.5 ms; flip angle, 30°; and 2 averages. Lesion area and number were quantified by 
multiple blind reviewers using ImageJ and Osirix software. 3D reconstructions were assembled using 
Osirix software by a blinded reviewer.
Middle cerebral artery endothelial function. Endothelial function assays are based upon 
previously published methods26. Middle cerebral artery endothelial function was performed as previously 
described. Mice (N=7-14/group) were euthanized via exsanguinations by cardiac puncture while under 
isoflurane anesthesia. Right and left middle cerebral arteries approximately 100-120 micrometers in 
luminal diameter were excised from the brain and placed in myograph chambers (DMT A/S, Aarhus, 
Denmark) containing EDTA-buffered physiological saline solution (PSS), cannulated onto glass 
micropipettes and secured with nylon (11-0) suture. Once cannulated, the middle cerebral arteries were 
warmed to 37°C and pressurized to 60 mmHg intraluminal pressure and allowed to equilibrate for 1 h. All 
arteries were then submaximally preconstricted with phenylephrine (2 ^M). Increases in luminal dia meter
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in response to increasing concentrations of the endothelium-dependent dilator acetylcholine (Ach; 1 x 10-9 
to 1x 10-4 M) in the absence or presence of the nitric oxide synthase inhibitor, L-NAME (0.1 mmol/L, 30 
min) or the superoxide scavenger, TEMPOL (1 mmol/L, 60 min) was assessed. Endothelium-independent 
dilation to sodium nitroprusside (SNP: 1x10-10 to 1x10-4 mol/L) also was determined (5). Arterial 
segments were imaged and diameters measured by an automated edge detection; VAS software (DMT A/S, 
Aarhus, Denmark). All dose response data are presented as a percent of possible dilation after 
phenylephrine preconstriction.
Noninvasive blood pressure measurements in conscious mice. Murine blood pressures were 
noninvasively measured by determining the tail blood volume with a volume pressure recording (VPR) 
sensor and an occlusion tail-cuff (CODA System, Kent Scientific, Torrington, CT) as previously described 
in detail. This method has been previously validated versus arterial catheter blood pressure. Blood pressure 
and heart rate recordings were made in a quiet and warm (24 C) environment. Mice were placed in 
restrainers on a heating unit and given 15-20 minutes to acclimate and reach a steady body temperature (30­
35 C). Each session consisted of 5-10 acclimatization measurements; if those measures were stable, they 
were followed by 20 experimental measures. Measures with aberrant movement/behavior or inadequate 
volume pressure measures were treated as outliers. Averages from each session were used for systolic 
blood pressure, diastolic blood pressure, mean blood pressure, and heart rate for each individual mouse.
Mouse experiments. All mouse experiments were approved by the University of Utah 
Institutional Animal Care and Use Committee or the George E. Wahlen Department of Veterans Affairs 
Medical Center Institutional Animal Care and Use Committee. Measures of serum 25(OH)D3 were made 
by ARUP clinical laboratories using standard clinical assays.
Biochemical assays. Wild-type, siCTRL or siCCM2 treated HMVEC-D cells were incubated 
with either 100 nM or 10^M cholecalciferol (Tocris), 7-DHC (Sigma) or vehicle (0.5% DMSO) for 60 
minutes (pMLC, ARF6, RAC, CDC42, RRAS) or 24 hours (RHOA), unless otherwise indicated. After 
treatment, the cells were washed with ice-cold PBS and lysed in 50mM Tris pH 7.4, 150mM NaCl, 10mM 
MgCl2, 10% Glycerol, 1% NP-40, 1X protease inhibitors, and 1X phosphatase inhibitors. For RhoA,
ARF6, Rac1 /cdc42 and R-Ras activation assays, crude total cell lysate were generated and GTP-RhoA, 
ARF6, Rac1/ cdc42 and R-Ras were precipitated with Rhotekin-RBD (Millipore), GGA3-PBD (Cell
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Biolabs), PAK-1-PBD (Millipore), and Raf-1 RBD, respectively. Following three washes with lysis buffer, 
bound proteins were eluted with 2X sample buffer. RhoA, ARF6, Rac1 /cdc42, and R-Ras were detected by 
western blotting with antibodies (RhoA, Rac1, and R-Ras antibody are from Cell Signaling, ARF6, and 
cad42 antibody are from Millipore). Each blot is representative of at least three independent experiments, 
for which quantification is shown.
Fluorimetric intracellular ROS detection. Briefly, EA-hy926 cells grown to confluence in 
complete medium were washed twice with PBS, incubated with 2',7'-dichlorfluorescein-diacetate (DCFH- 
DA) at a final concentration of 5^M in PBS at 37°C for 30 minutes and analyzed by Tali image based 
cytometer (Invitrogen). Raw data were elaborated by Flowing software (v. 2.5.0, by Perttu Terho, 
University of Turku, Finland).
Statistics. Data presented are mean ± SEM unless otherwise indicated. Statistical significance is 
indicated generally by a single symbol (i.e. *) to indicate P < 0.05, two symbols (i.e. **) to indicate P <
0.01, three symbols (i.e. ***) to indicate P < 0.001, and so on. Standard statistical analysis was used. For 
comparisons of two groups, a Student’s T-test was performed. For comparison of more than three groups, 
1-way ANOVA with Tukey’s or Bonferroni’s multiple comparison post hoc analysis was utilized. For 
comparison of data with at least two grouping variables, a two way ANOVA was used. Significance was 
set at P < 0.05 for all experiments.
CHAPTER 6
CONCLUDING REMARKS
During my time as a graduate student in the laboratory of Dr. Dean Y. Li, I have had the privilege 
to work on a number of projects. Through my investigation of the role of elastin in the endothelialization 
of intravascular devices, to my investigation of the role of the small GTPase ARF6 in both vascular 
stability and vascular mechanotransduction, I have been building a suite of tools that would enable me to 
use the mouse model of CCM disease we developed to perform translational research to try to bring drugs 
to patients with CCM disease. This final project, identification of two new treatments for CCM disease, 
was the culmination of all of my work detailed in Chapters 1-4. In Chapter 5, I laid out my final major 
work, in which we conceived and implemented a high-content screen querying both structural and 
functional cellular phenotypes to discover novel factors active in the CCM2 pathway. We combined high- 
content imaging, machine-learning software, as well as trans-cellular electrical resistance measurements as 
efficient and powerful tools for drug screening. We specifically focused on known drugs and bioactive 
compounds because we believe such drugs have a much higher chance of making a rapid impact on patient 
outcomes. By focusing on such molecules, our high-tech screening method, which combines advances in 
molecular biology, imaging, and computing, has led to a low-tech solution: the potential for a modulatory 
role of an inexpensive widely-available drug with a wide safety margin on a disease for which no 
pharmaceutical intervention has yet been approved.
Of particular excitement to us are recent advances by other groups who have expanded our 
understanding of the pathophysiology of CCM disease and who have, in some cases, put forth potential 
treatments for the disease. In particular, recent evidence suggests that endothelial to mesenchymal 
transition (endMT) plays a critical role in the pathophysiology of CCM disease31. Through inhibition of 
TGF-P, a key driver of endMT, reduction in severity of disease in a mouse model of CCM disease was 
identified. Interestingly, the target of tempol, oxidative stress, drives and is driven by increased TGF-P 
signaling and endMT32. Additionally, metabolites of cholecalciferol have also been shown to strongly
100
inhibit TGF-P signaling and epithelial-mesenchymal transition (EMT)33,34. We have also shown here that 
RHOA activation, proposed by us and others as critical in CCM pathophysiology, is inhibited by both 
cholecalciferol and tempol. Taken together, these studies suggest that both compounds identified in a 
completely unbiased manner in our screen could be inhibiting pathways previously shown to be critical for 
CCM pathogenesis. The accessibility of cholecalciferol at trivial cost to patients, and the myriad clinical 
trials underway in the United States for tempol in a variety of conditions suggest that one or both of these 
drugs could be rapidly applied to the treatment of CCM disease. Moreover, their identification provides an 
avenue toward discovery of additional molecular mechanisms relevant to CCM disease.
Future work will determine whether our findings, obtained in both human endothelial cells and a 
mouse model of CCM disease, will fully translate to humans with CCM disease. Our findings underline 
major priorities upon which the field must agree. Specifically, success of any clinical trial, especially in 
rare disease research, hinges upon well-studied natural history and clinically meaningful endpoints. The 
long-term sustainability of treatment often also relies on establishment of relevant biomarkers. In advance 
of, or in conjunction with, human clinical trials for cholecalciferol or tempol treatment, our work strongly 
supports immediate amendment of research protocols on human patients with CCM to include 
measurement of both 25(OH)D3 and an agreeable marker of oxidative stress. We must also develop 
widely-acceptable standards for tracking the natural history of CCM, including specific imaging modalities, 
lesion evaluation, and symptom assessment. We must use these standards as a platform by which to 
perform both observational and interventional studies of and CCM disease and treatments such as 
cholecalciferol. As with any rare condition, the probability of success is exponentially enhanced by 
agreement and adherence of the field to specific protocols so that data can be aggregated across clinical 
sites.
Finally, the opportunities to easily adapt the screening system described herein to effectively 
search for new therapies for a large and diverse set of monogenic diseases is perhaps the most exciting 
aspect of this project. By combining the platform we propose here with libraries of repurposable drugs, we 
are hopeful that we and others can quickly and efficiently bring new treatments to patients with many 
monogenic loss of function diseases that otherwise may not be the target of pharmaceutical discovery. 
However, we must be strategic in this approach; our success in identifying novel treatments for CCM was
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and will continue to be enabled by a strong animal model and a reasonably strong understanding of the 
natural history of the disease. Therefore, our expansion of this unbiased drug discovery platform to other 
monogenic diseases will require us to selectively apply a bias toward studying those diseases in which 
strong preclinical models and clinical knowledge exist. Some might argue that though this platform has the 
potential to affect many diseases, the reach of the system in terms of the total number of patients affected 
might be low. This would be to ignore, however, that rare diseases have a proven track record of enabling 
the study of, and treatments developed for, some of the most widely used drugs in medicine35.
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Development of a vibration and compression countermeasure device for bone 
and muscle loss in microgravity environments.
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Summer 2002 Field Researcher
Dr. Barry Sullender
Rice University, Department o f  Ecology and Evolutionary Biology 
Independent research project studying the effects of parasite loads on non-native 
B. marinus toads in tropical Mexico.
Research Publications and Reports
Gibson, C.C., Zhu, W., Davis, C.T., Bowman-Kirigin, J.A., Chan, A.C., Ling, J., Shiu, Y.T., Whitehead, 
K..J., Li, D.Y., Vitamin D directly stabilizes the endothelium and suppresses a hereditary stroke syndrome. 
(Submitted)
Wilkins, J.R., Gibson, C.C., Pike, D.B., Iwamoto, M.N., Kubota, A., Shiu, Y.T., Roles of cyclic stretch 
and actin filaments in bFGF-mediated sprouting angiogenesis. (Submitted).
Wilkins, J.R., Gibson, C.C., Pike, D.B., Iwamoto, M.N., Kubota, A., Shiu, Y.T. Differential effects of 
cyclic stretch on bFGF- and VEGF-induced sprouting angiogenesis. (Submitted).
Wilkins, J.R., Pike, D.B., Gibson, C.C., Li, L., Shiu, Y.T., The interplay of cyclic stretch and vascular 
endothelial growth factor in regulating angiogenesis. (Submitted).
Zhu, W.*, London, N.R.*, Gibson, C.C.*, Tong, Z., Sorenson, L.K., Shi, D.S., Guo, J., Davis, C.T., Smith, 
M.C.P., Grossmann, A.H., Thomas, K.R., Li, D.Y. Interleukin receptor activates a MyD88-ARNO-ARF6 
cascade to disrupt vascular stability. Nature. 492: 252-255. 2012 
*Co-First Authors
Jones, C.F., Campbell, R.A., Franks, Z., Gibson, C.C., Thiagarajan, G., Vieira-de-Abreu, A., 
Sukavaneshvar, S., Mohammad, S.F., Li, D.Y., Ghandehari, H., Weyrich, A.S., Brooks, B.D., Grainger, 
D.W. Cationic PAMAM dendrimers disrupt key platelet functions. Molecular Pharmaceutics. 4:9(6): 
1599-1611. 2012.
Chan, A.C., Drakos, S.G., Ruiz, O.E., Smith, A.C.H., Gibson, C.C., Ling, J., Passi, S.F., Stratman, A.N., 
Sacharidou, A., Revelo, M.P., Grossmann, A.H., Diakos, N.A., Davis, G.E., Metzstein, M.M.m Whitehead, 
K.J., Li, D.Y. Mutations in 2 distinct genetic pathways result in cerebral cavernous malformation in mice. 
Journal of Clinical Investigation, 121(5): 1871-1881. 2011
Wilson, B.D.*, Gibson, C.C.*, Sorensen, L.K., Guilhermier, M.Y., Clinger, M., Kelley, L.L., Shiu, Y.T., 
Li, D.Y. Novel Approach for Endothelializing Vascular Devices: Understanding and Exploiting Elastin- 
Endothelial Interactions. Annals of Biomedical Engineering 39(1): 337-346. 2011 
*Co-First Authors
Gibson, C.C., Puleo, D.A., Bizios, R. “Cell and Tissue Interactions with Materials: The Role of Growth 
Factors.” in Biological Interactions on Material Surfaces. Ed. Puleo, D.A., Bizios, R. Springer. (2009).
Presentations and Posters
Gibson, C.C., Davis, C.T., Ling, J., Shiu, Y.T., Lesniewski, L.A., Donato, A.J., Whitehead, K.J., Li, D.Y. 
“A High-Content Screen Identifies Novel Therapeutics for a Hereditary Stroke Syndrome” University of 
Utah Research Trainee Symposium. Deer Valley, Utah. September 13th, 2012.
Gibson, C.C., McCullagh, J.P., Mleynek, T.M., Shiu, Y.T., Lesniewski, L.A., Donato, A.J., Whitehead, 
K.J., Li, D.Y. “CCM2 Regulates Superoxide and Nitric Oxide in the Endothelium” International Angioma 
Alliance Meeting. Paris, France. November 17th, 2011.
Melia, B., Gibson, C.C., Fernandez, E., Clark, D., Felton, J., Fielding, S., Gray, M., Koller, J., Norwood, 
A., Spurlock, R., Nierenberg, N., Ulysse, J.C., Berggren, R. “Sustainable Healthcare in the Central Plateau 
of Haiti.” University of Texas Medical Community Service Learning Conference, Poster and discussion 
panelist. April 2, 2009.
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Gibson, C.C., Rooney, T., Elam, A., Metwalli, Z., Robb, R., Liebschner, M., “Advanced Space Health 
Maintenance System: Technology Enabling Extended Manned Space Exploration”. Conference 
Proceedings: SPACE 2005, Long Beach, CA. October 2005.
Gibson, C.C., Rooney, T., Elam, A., Metwalli, Z., Robb, R., Liebschner, M., “STEVE: Spine and 
Trochanter External Vibration Effector”. Conference Proceedings: Revolutionary Aerospace Academic 
Linkage, Cape Canaveral, FL. May, 2005.
Patents
William Marsh Rice University. Inventors: M. Liebschner, C. Gibson, T. Rooney, A, Elam, Z. Metwalli, 
and R. Robb. 2006. Vibration and Compression Countermeasure Harness and Belt for Bone and Muscle 
Loss in microgravity. Patent Cooperation Treaty Application. WO/2006/110545, filed Oct. 19, 2006. 
Patent Pending.
Industry Experience
2004 -  2005 Project M anager
Medi-Screw, Inc., Portland, Oregon
Life-Science startup company; developed novel pedicle-screw head system for 
increased operating room control. Managed manufacturing, directed research 
plan, and developed research protocols. Reported directly to CEO.
Summer 2004 Business Development Intern
Medi-Screw, Inc., Portland, Oregon
Wrote business plan, created venture capital presentations, presented to venture 
capitalists, and researched customers and markets. Primary liaison to project 
engineer.
Teaching Experience
2011-present M entor, Research mentor to young graduate students, one post-baccalaureate 
student, and two high school students working in the Li Lab.
Dr. Dean Y. Li 
The University of Utah
2010 -  2011 Teaching Assistant and Lecturer, Physics o f  the Human Body. 
The University of Utah
Summer 2007 Teaching Assistant, Human Gross Anatomy, CSBL 5019.
Dr. Ron Philo.
The University of Texas Health Science Center at San Antonio
Spring 2006 Teaching Assistant, Advanced Biomaterials, M E 6973 
Dr. Jeffrey Y. Thompson.
The University of Texas at San Antonio
Leadership, Honors, and Awards
2009 Member, UTHSCSA Energy Conservation Committee, Appointed by Executive
















Selected Participant, American Medical Student Association Environmental 
Health Leadership Institute, Mount Sinai School of Medicine.
President and Founder, ‘Sustainability Club’ student group, UTHSCSA.
Co-President and Co-Founder, “Project Haiti’ student group, UTHSCSA.
Greehey MD/PhD Scholarship, University of Texas Health Science Center at 
San Antonio. Tuition, benefits, and $21,500 yearly stipend.
UT Health Sciences Center at San Antonio Alumni Merit Award for service to 
the University, First-Year Medical Student - $1000.00.
Big Brothers and Big Sisters of South Texas ‘Big Couple’ of the Year.
UTHSCSA Green Initiative Student Leader. Worked with Executive VP, 
created “Green Initiative Task-Force”. New building policies, recycling 
policies, energy policies, and other ‘green’ policies instituted campus-wide.
President, Biomedical Engineering Society, Joint Ph.D. Program in Biomedical 
Engineering at the University of Texas Health Science Center at San Antonio 
and the University of Texas at San Antonio.
First Place Team, Revolutionary Aerospace Academic Linkage Undergraduate 
Research and Design Competition. Kennedy Space Center, Florida.
Nine team awards including “Legends Award”, Texas Space Grant Consortium 
Undergraduate Research and Design Competition Spring Design Challenge. 
Johnson Space Center, Texas.
Six team awards including “Best Poster” and “Best Presentation”, Texas Space 
Grant Consortium Undergraduate Research and Design Competition Fall Design 
Challenge. Johnson Space Center, Texas.
Undergraduate Representative, 2004 Rice University, Dean of Engineering 
Search Committee (Appointed).
College Representative, Martel College, Rice University (Elected).
Western Athletic Conference (WAC) Scholar-Athlete, NCAA Division 1 Men’s 
Track and Field.
Rice University Men’s Track and Field Team. NCAA Division-1. Decathlon.2001-2003
Medical Arts, Writing, and Ethics -  Electives and Publications
2013 Christopher C. Gibson. Why the conversations that start in TEDMED need to
continue. Guest Column. KevinMD.com, May 11th, 2013
2010 Writing Medical Experience3 Medical Elective Education, University of Utah.
2010 Christopher C. Gibson. Haitians Can Teach Us. Opinion Column. Deseret
News, January 16th, 2010.
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2010 Christopher C. Gibson. Reaching out to a devastated Haiti. Opinion: letters.
New York Times, January 14th, 2010.
2008-2009 Literature and Medicine, Medical Student Elective Education, UTHSCSA.
2008 The History o f  Anatomy, Medical Student Elective Education, UTHSCSA.
2008 Issues in Death and Dying, Medical Student Elective Education, UTHSCSA.
Volunteering and Service
2009 Participant, UTHSCSA medical service trip to Thomonde, Haiti.
2009 UTHSCSA Haiti Nutrition Center Fundraising Leader.
2008 Trip-leader, Inaugural UTHSCSA medical service trip to Thomonde, Haiti.
2006 -  2009 Big Brother
Big Brothers and Big Sisters o f  South Texas
